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Abstract
Background: This project utilized opioid-misusing adults to investigate the association between
type of opioid misuse and perceived readiness, financial, structural, and stigma-related barriers to
accessing SUD treatment; identified classes of PSU and the association between patterns of PSU
and perceived barriers, and evaluated effectiveness of an out-of-hospital opioid-treatment
connection program.
Methods: Respondents from 2015-2018 NSDUH included insured adults reporting past year
opioid misuse. Multivariate logistic regression assessed relationship between type of opioid
misuse and perceived barriers to SUD treatment. LCA identified patterns of PSU, and
multivariate logistic regression assessed association between PSU classes and perceived barriers.
EMS ePCRs for nonfatal OOD from February 1st 2016 – January 31st 2020 were utilized for
SITSA and MITSA to evaluate association between implementation of an out-of-hospital opioidtreatment connection program and monthly trend of nonfatal OOD in the county of
implementation and a control county.
Results: Of 6,095 individuals, 3.7% perceived at least one barrier. LCA identified: Heroin
injectors with high PSU, PPR users with low PSU, and PPR users with high PSU. Heroin
injectors with high PSU faced significantly greater odds of perceiving readiness, structural, and
stigma-related barriers compared to PPR users with low PSU. The county of implementation
reported an immediate decrease in nonfatal OOD by 0.34% each month post-intervention,
however there were no significant differences in pre- to post-intervention level or slope between
counties.
Conclusions: The findings of this study can be used to develop public-health interventions
targeted towards subpopulations perceiving barriers, and continue evaluation of out-of-hospital
intervention programs.
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Chapter 1: Background
1.1 Human and Economic Toll of the United States Opioid Epidemic
In 2017, a total of 47,600 opioid-related fatalities occurred in the United States –
approximately 130 Americans killed every day.1 The annual number of drug overdose deaths in
the United States has nearly tripled since 1999; with opioids, both prescription (oxycodone,
oxycontin) and illicit (heroin, fentanyl), accounting for more than half of the lives claimed during
that time period.2 The mortality resulting from the opioid epidemic is responsible for destroying
families, consuming public safety resources and burdening the U.S. healthcare system. In
November of 2017 the White House Council of Economic Advisers reported the total economic
cost of the opioid crisis at close to $504 billion,3 with more than a third of that total economic
burden likely made up of costs from reduced productive hours due to misuse/dependence, and
expenses to the U.S. healthcare system.4
1.2 Opioid Addiction Treatment in the United States
The abrupt cessation of opioids may lead to strong cravings or intense symptoms of
opioid withdrawal, which may encourage an individual to seek out and use opioids.5 To break
the cycle of abuse, there are a variety of therapies which can be used to treat Opioid Use
Disorder (OUD), including pharmacotherapies, behavioral therapies, and a combination of both.
These treatments take place in a variety of settings throughout in the US; overall the majority
(91.3%) take place in outpatient programs, followed by residential programs (7%), and hospital
inpatient program (1%).6
Pharmacotherapies. Evidence suggests that treating opioid addiction with medication is
far more effective at keeping individuals in treatment and opioid-abstinent than using nonmedication treatment.7 Three medications are currently approved by the U.S. Food and Drug
Administration to treat OUD: opioid-agonists methadone and buprenorphine, and the opioid-

2

antagonist naltrexone.8 While sometimes mistaken as “heroin/opioid substitutes”, the effects of
these medications differ from those of heroin and other misused opioids.9 Whereas the rapid
onset of heroin produces immediate euphoria followed by a crash, methadone and buprenorphine
have gradual onsets of action and maintain stable levels within the brain, decreasing an
individual’s craving for opioids without a euphoric high.9 In 2017, facilities with opioid
treatment programs reported more than a half-million individuals participated in medicationassisted opioid therapy, 73.9% received methadone, 21.7% buprenorphine, and 4.5% received
Naltrexone.6
Behavioral therapies. Behavioral therapies help engage people in treatment for substance
use disorder (SUD), enabling them to modify their attitudes toward opioid use, and help them
develop coping mechanisms to handle physical and environmental cues that may trigger intense
cravings for opioids.9 Although maintenance on medication-assisted treatments alone has been
effective at reducing overdose deaths,10 research has also shown that both methadone and
buprenorphine maintenance are more effective when included with some type of behavioral
therapy.9 This is likely why the American Society of Addiction Medicine recommends
psychosocial treatment in conjunction with any pharmacological treatment for OUD.5
Despite the increased availability of treatment over the past decade,11 most individuals
with OUD report no use of OUD treatment.12 Additional steps need to be taken to identify and
address the variety of financial, structural, and stigma-related barriers that prevent individuals
from accessing the treatment they need.
1.3 Barriers to Accessing Treatment for Substance Use Disorder
The gap for treatment of SUD is massive, that is, among those who need treatment for a
SUD, few receive it.9 Between 2016 and 2017, the National Survey on Drug Use and Health
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(NSDUH) estimated 17,484 individuals needed but did not receive treatment for substance use in
the past year.13
Perceived Need of Treatment. This gap primarily exists due to the substantial number of
individuals who do not perceive a need for treatment of their substance use.14,15 In a 2015 survey
conducted by Ali et al., 97% of respondents with a SUD reported not feeling a need for treatment
or counseling for their alcohol or substance use.15 This perception persists because individuals
are not be ready to stop using alcohol or drugs,15 believe they can handle their addiction on their
own,16,17 or are not prepared to stop using alcohol or drugs.15 Yet, even among the small group of
individuals feeling a need for treatment, barriers to accessing treatment for SUD persist.
Financial barriers. Financial barriers are commonly cited by individuals acknowledging
a need for SUD treatment,10,18–20

21

with individuals not seeking help due to an inability to pay

for treatment,10,18,20,22 most often due to a lack of insurance.20,22 One study estimated around 12
million uninsured Americans had a diagnosable mental or SUD,23 and Wu et al. found that
uninsured adults are disproportionately affected by OUD.12
Structural barriers. These financial barriers are likely exacerbated by the wide variation
in the types of treatment for SUD and treatment coverage available in each state,24 which
contribute to a variety of structural/organizational barriers. Restrictions placed on medications
used in treatment can lead to a shortage of providers available to provide treatment,10,25–27 further
impeding access by creating long waiting periods.28 Limited availability of programs
disproportionately affects individuals living in rural areas,18 as well as vulnerable populations in
need of special treatment accommodations, such as individuals who are pregnant,29 or those with
co-occurring psychiatric disorders30 or disabilities.31
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Stigma-related barriers. Lastly, stigma-related barriers are often cited for deterring
individuals from seeking treatment, stemming primarily from a general lack of understanding
about treatment for SUDs.18,31–34 Some individuals report not seeking treatment due to a lack of
community support,18,31 and due to the belief that using medication assisted treatment was
equilivant to substituting one addiction for another.18,34 In other cases the treatment itself was an
issue, as individuals reported not wanting to seek treatment due to stigmatization and judgement
from clinicians and agency personnel.31,32
In order to address these barriers and reduce the treatment gap, strategies must be
implemented to increase access to treatment for SUD, such as: achieving insurance parity,
reducing stigma, and raising awareness among both patients and clinicians about value of
addiction treatment.9
1.4 Addressing Barriers through the Patient Protection and Affordable Care Act
The United States government attempted to address many of these barriers to health care
access through the Patient Protection and Affordable Care Act (ACA). The ACA aimed to
increase healthcare access in three different ways: i) by extending insurance coverage through
Medicaid expansion and state health insurance exchanges, ii) by requiring coverage of the
essential health benefits package, including SUD screening and treatment services under both the
Medicaid expansion program and the health plans offered on the state healthcare exchanges, and
iii) by extending the 2008 mental health parity and addiction equity act: requiring insurers to
cover SUD treatment in a no more restrictive way than medical and surgical services.23,24
Since full implementation of the ACA in 2014, significant strides to increase healthcare
access have been made: 22 million Americans gained access to insurance, essentially decreasing
the number of uninsured Americans by half, from 48.6 million in 2010 to 28.6 million in 2015,35
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and decreasing the rate of uninsurance for nonelderly adults to 10.2%.36 Studies have shown that
the provisions of the ACA have greatly expanded the ability of individuals with SUD to obtain
and maintain coverage.23
In 2014, 81.5% of the respondents to the NSDUH with serious mental health or SUD
reported insurance, a significant increase from all pre-2014 time periods,37 and another study
from Feder et al. reported the prevalence of uninsured individuals with heroin use disorder
declined dramatically from 2010 to 2015, largely due to the increased prevalence of Medicaid
coverage.21
Many researchers have credited the expansion of Medicaid as the driving force for many
of the improvements in uninsurance;24,36,38
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Medicaid insured 13 million Americans,35

including 1.6 million with SUD who gained insurance coverage in the Medicaid expansion
states.24 Medicaid also accounted for the vast majority of new coverage among individuals with
SUD, with use of Medicaid as a source of payment for SUD treatment increasing from 19.6% in
2011-2013 to 27% in 2014.38
Implementation of the ACA was not only instrumental in increasing the number of
insured individuals with SUD, it also led to the proliferation of facilities offering SUD treatment
and decreased the restrictions, requiring SUD treatments to be offered on par with medical and
surgical procedures.24 Across the US, coverage for addiction treatment generally improved from
2013-2017; the proportion of state plans providing benefits for residential SUD treatment and
access to OUD medications dramatically increased, and annual service limits on outpatient
addiction treatment decreased from 34% to 19% in standard plans.39
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1.5 Enrollment in Substance Use Disorder Treatment following the ACA
Despite increases in insurance coverage and OUD medication availability following
implementation of the ACA, the treatment rates for alcohol and SUDs have remained unchanged,
as studies have reported no significant differences in SUD treatment utilization even up to three
years following ACA implementation.21,37,40
One factor significantly impacting enrollment in SUD treatment is variation in the
expansion of state Medicaid programs.41,42 ACA allowed states to expand Medicaid to
individuals whose incomes were at or below 138% of the federal poverty level;41 however, a
2012 decision of the United States Supreme Court enabled states to choose whether or not to
expand Medicaid, resulting in 19 states choosing not to expand.41 In 2017 the rate of uninsurance
in non-expansion states was 2.5 times higher than in the expansion states, as many low-income
individuals who make too much money to qualify for Medicaid but not enough to be able to
afford a plan on the health care exchange.36 Medicaid was meant to play an important role in
providing access to OUD treatment, as the program currently covers 30% of the 2.2 million
Americans with prescription OUD.7 Thus, one possible explanation for stagnant enrollment in
SUD programs could be because individuals in need of SUD treatment remaining uninsured
because they reside in a non-expansion state.
While many studies have focused on the persisting treatment access barriers of uninsured
individuals, few have investigated the barriers experienced by insured individuals. While
individuals who are insured are less likely to experience financial barriers to accessing treatment,
they may continue to experience structural, motivational, and stigma-related barriers to accessing
SUD treatment.20 For example, insured individuals may face barriers to access due to a lack of
treatment availability. A shortage of physicians able to provide SUD treatment limits treatment
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availability, and more than 30 million people live in U.S. counties without a single prescriber of
medications for addiction treatment.10 Although one study showed that the number of physicians
able to prescribe buprenorphine dramatically increased between 2003-2012, the demand for
treatment in 2012 continued to overwhelm the capacity of available programs, with the majority
of states reporting a treatment gap of at least 3 patients per 1000 people, and an overall gap of
nearly 1 million people nationally.11
Access to treatment among the insured may also be limited by service restrictions
imposed by an individual’s insurance, such as restrictions on OUD medications used in
treatment.43,44 One study sampling 100 policies on health insurance marketplaces found that
plans were less likely to cover buprenorphine and naltrexone,45 and reported that buprenorphine
was more likely than methadone to be subject to prior authorization and restrictions.45 In
addition, clinicians report low reimbursement rates for OUD medications as a significant barrier
to implementing addiction services program,26 leading some clinicians to decline accepting
insurance for addiction services at all.25 Among those insured, those who are likely impacted
most by service restrictions are individuals with Medicaid, as the benefits available vary widely
from state-to-state.39,43 One promising study by Andrews et al. reported that Medicaid benefits
for addiction treatment generally improved between 2014 and 2017: the proportion of state plans
providing benefits for residential treatment and OUD medications states increased and the
proportion of services and medications subject to annual limits decreased.39 Yet this study also
reported that 15 states continued to prohibit coverage for short-term residential treatment, and
only half provided coverage for long-term treatment.39 Variation in the services reimbursed
cause many Medicaid recipients difficulty locating treatment facilities,22 especially facilities
offering medications for addiction treatment.43 Alas, even when individuals with Medicaid find a
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facility they may not be prioritized as patients or receive treatment equal to that received by
individuals with private insurance, due to the lower fees reimbursement paid by Medicaid.35
1.6 Shortcomings of Strategies Currently Addressing the Opioid Epidemic
In addition to implementing the ACA, the United States has launched and promoted a
variety of public health initiatives aimed at preventing opioid-related morbidity and mortality.
Table 1.1 summarizes these strategies and their prevalence throughout the United States, and
categorizes them as either “primary prevention” or “tertiary prevention” strategies, based on the
three types of prevention strategies used by epidemiologists in response to disease epidemics.46
Primary prevention aims to reduce the incidence of a disease or condition.46 Primary
prevention strategies to address the opioid epidemic include prescription monitoring programs
(PMP), which allow physicians to monitor the number of prescriptions a patient receives to deter
overprescribing or “doctor shopping”,7,47,48 prescription limits which encourage physicians to
limit the number of opioids in an initial opioid prescription,7 and prescription drug take-back
programs, which allow individuals to dispose of unused opioid medications to prevent diversion
or misuse.49 These initiatives aim to decrease the incidence of opioid misuse by limiting the
number of prescribed opioids available for misuse.
Tertiary prevention aims to prevent further disease through therapeutic and rehabilitative
measures after a disease has been diagnosed.46 The majority of strategies addressing the opioid
epidemic in the United States are tertiary prevention strategies, which aim to prevent future
morbidity or morbidity associated with opioid misuse. Overdose fatalities could be further
prevented by increasing public and layperson access to naloxone through overdose education
and naloxone distribution programs50–53 and over-the-counter availability of naloxone,54,55 by
ensuring overdose bystanders can call 911 without fear of arrest, as decreed in Good Samaritan
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Legislation (GSL),55 or by allowing individuals to use pre-obtained drugs under the watch of
trained staff in supervised drug consumption venues.56,57 In addition, the incidence of Human
Immunodeficiency Virus (HIV) and Hepatitis C resulting from risky drug injection practices can
be decreased through syringe-needle access programs.46
Although one or more of these programs has been implemented in nearly every state in
the nation,7 it is concerning that none of these initiatives employ secondary prevention, which
emphasizes the screening of individuals for a health condition before it leads to serious
complications.46 Upon screening an individual with OUD, a clinician could connect that
individual with further addiction treatment, assisting them to bypass the various treatment access
barriers discussed previously. While tertiary strategies are critical to decreasing the morbidity
and mortality associated with the opioid epidemic, these strategies often end with detoxification,
the first stage of addiction treatment, which by itself does little to change long-term drug use.9 To
stop an addicted individual from compulsively seeking drugs and end the long-term cycle of
abuse, drug treatment is a necessity,9 and identifying ways to connect individuals with addiction
treatment is critical.
1.7 Literature Summary
Opioid treatment is the most effective way to overcome an opioid addiction, yet the
number of individuals receiving treatment remains low. In the past, many of the barriers
preventing an individual from seeking care were financial, due to lack of insurance and inability
to pay out of pocket for treatment. The ACA was implemented in order to decrease financial
barriers to accessing healthcare, and while the ACA greatly expanded access to insurance,
enrollment into treatment for substance use disorder has remained unchanged. Although some
studies have investigated the relationship between treatment enrollment and Medicaid expansion,
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few have explored barriers to accessing treatment for SUD among insured individuals, and fewer
still have focused on barriers to accessing OUD treatment. Additionally, although treatment
initiatives in the United States have been effective in reducing the harm associated with opioiduse, very few initiatives have focused on promoting the screening of OUD and connecting
individuals with OUD to the addiction treatment they require.
The aim of this dissertation was to address these research gaps by a) further investigating
how sociodemographic and substance use characteristics are associated with barriers to accessing
treatment for SUD, and b) evaluate the effectiveness of an out-of-hospital opioid treatment
connection program on the number of nonfatal opioid overdoses.
This dissertation pursued these study objectives through the investigation of three aims:
1. Investigate the association between type of opioid misuse and perceived readiness,
financial, structural, and stigma-related barriers to accessing treatment for substance
use disorder among insured adults reporting past year opioid misuse.
2. Identify patterns of past year polysubstance use among a nationally representative sample
of opioid-misusing adults in the U.S. and evaluate the association between class of
polysubstance use and perceived readiness, financial, structural, and stigma-related
barriers to accessing treatment for SUD.
3. Evaluate the impact of an out-of-hospital opioid treatment connection program on the
number of nonfatal opioid overdoses 24-months post intervention.
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Chapter 2. The association between type of opioid misuse and perceived barriers to
accessing addiction treatment among insured opioid-misusing individuals
Abstract
Background: Little is known about the relationship between type of opioid misuse and access to
treatment for substance use disorders. We investigated the association between type of opioid
misuse and perceived readiness, financial, structural, and stigma-related barriers to accessing
treatment for substance use disorder (SUD) among insured individuals reporting past year opioid
misuse.
Methods: Participants from the 2015-2018 National Survey on Drug Use and Health included
insured individuals reporting past year misuse of prescription pain relievers (PPR), heroin (HO),
or both (H+PPR). Chi-square analyses determined the association between participant’s
predisposing, enabling, and need characteristics and type of opioid misuse. Multivariate logistic
regression assessed the relationship between type of opioid misuse and all four perceived barriers
to accessing treatment for SUD.
Results: Of the 6,095 individuals reporting past year opioid misuse, 244 (3.7%) perceived at
least one barrier to accessing treatment for SUD. Whereas HO users most often perceived
financial (50.5%) and stigma-related (39.8%) barriers, readiness (45.5%, 50.9%) and structural
(41.2%, 44.9%) barriers were most cited by those using PPR or H+PPR. Misuse of H+PPR and
HO (vs. PPR only) significantly increased the odds of perceiving readiness (OR=2.80,
95%CI=1.08-7.27), structural (OR=3.27, 95%CI=1.26-8.46), and stigma-related (OR=3.98,
95%CI=1.42-11.21) barriers. Severe mental health symptoms and increased number of SUD also
significantly increased the odds of perceiving all four barriers.
Conclusions: Type of opioid misuse, mental health severity, and number of SUD are
significantly associated with perceived barriers to accessing treatment for SUD. Targeted
strategies that address individual-level factors (e.g., severe mental health problems, multiple
SUD, type of opioid misuse) alongside population-level changes that increase availability of
services may increase the likelihood of enrollment into treatment for SUDs.
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2.1 Introduction
Treatment of Opioid Use Disorder (OUD) is the most effective way to treat opioidrelated addiction and reduce the burden of this substance on the American health care system.
Failure to enroll more individuals with OUDs into treatment has been costly to the U.S.
healthcare system. In 2017 alone, a total of 47,600 opioid-related fatalities occurred in the United
States. Further, the U.S. Council of Economic Advisors estimated the total economic cost of the
opioid crisis in 2015 to be $504 billion.3
The 2010 implementation of the Patient Protection and Affordable Care Act (ACA)
extended private and public insurance coverage to millions of Americans. It also included
screening and treatment services for substance use disorders (SUD) as essential benefits in health
insurance plans, and required insurers to cover behavioral health services, including SUD
treatment.23,58 Following implementation of the ACA, there were improvements in insurance
rates among opioid-misusing individuals and increased availability of SUD treatment
services.39,59,60 40 However, to date, there have been no significant differences in SUD treatment
utilization even up to three years following implementation of the ACA.21,37,40
It is likely that the ACA did not fully address four main barriers that reduce the likelihood
of seeking SUD treatment, including: motivational (not yet ready to quit substance use or believe
they can handle the addition on their own),17 financial (lack insurance or cannot afford
treatment),22 structural (medication restrictions, long waiting periods, lack of availability,
transportation),61–64 and stigma-related barriers (lack of community/family support, judgement
from clinicians and healthcare providers)65–67.
The recent shift in the type of opioid misuse from prescription opioids to heroin and
synthetic opioids represents a structural barrier not fully addressed by the ACA and may have
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contributed to an increase in opioid use rather than encouraging accessing opioid treatment.68,69
The mortality rate due to synthetic opioids increased by 45.2% between 2016-2017. In contrast,
prescription-opioid mortalities plateaued during this same timeframe.1 This is likely due to the
influx of synthetic opioids such as fentanyl,70 which made heroin and synthetic opioids a more
accessible alternative to prescription opioids.71 The shift in the type of opioid misuse had swift
implications for the planning of harm reduction and SUD treatment initiatives.
Overall enrollment in SUD treatment programs remains low among opioid-misusing
individuals, despite continued efforts to expand insurance coverage and access to SUD treatment.
While there has been a great deal of research on the barriers to accessing SUD treatment, to date
no study has investigated the barriers perceived by individuals who have insurance. In addition,
the national shift in type of opioid misuse over the past decade could impact how opioidmisusing individuals perceive the accessibility of SUD treatment. No study has investigated the
relationship between the type of opioid misuse and perceived barriers to accessing treatment for
SUD. This study aimed to gain a better understanding of the relationship between type of opioid
misuse and perceived barriers to accessing SUD treatment among insured adults in the United
States. Therefore, the objective of this study was to investigate the association between type of
opioid misuse and perceived barriers to accessing SUD treatment.
2.2 Methods
2.2.1 Data Source and Population
This study analyzed data from the 2015-2017 publicly available files of the National
Survey on Drug Use and Health (NSDUH). The NSDUH is administered to the noninstitutionalized civilian population aged 12 and older,72 collecting detailed information on the
use of alcohol, illicit drugs, mental illness, SUDs, utilization of behavioral health treatments, and
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treatment barriers for behavioral health conditions and treatments.73 The NSDUH uses a
stratified multistage area probability sample designed to represent each of the 50 states and the
District of Columbia.72 The methodological process for the NSDUH aims at increasing the
accuracy of self-reports, through the use of computer-assisted personal interviewing, audio
computer-assisted self-interviewing, and assurances that individual responses will remain
confidential.72 Data from 2015-2017 was chosen to represent the survey years when the ACA
was fully implemented throughout the United States. Most provisions of the ACA were
implemented by October of 2014, however there remained state-by-state variation for the
implementation of others.74 For example, although the ACA called for states to expand Medicaid
to individuals whose incomes were at or below 138% of the Federal poverty line,42,75 19 states
initially declined to do so. Thus, data from 2015 and beyond was chosen to give the most
accurate representation of perceived barriers to treatment that continue to persist after
implementation of the ACA.
The study population was made up of all individuals who reported past year misuse of
prescription pain relievers (PPR), heroin (HO), or both heroin and PPR (H+PPR). The
population included insured individuals between the ages of 18-64, to focus on the perceived
barriers of individuals most likely to have obtained insurance as a result of the ACA.
2.2.2 Outcome Variables
The dependent variables in this study were four binary indicators (yes/no) for perceiving
a readiness, financial, structural, or stigma-related barrier to accessing initial or additional
treatment for SUD within the past 12 months. Membership in each barrier category was assigned
from 11 responses to the question “Which of these statements explain why you did not get the
treatment or counseling you needed for your use of [substance]?”.72 Responses used to assign
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barrier categories were similar to those used in previous studies, 21,37,73 these barriers are
described in detail in Supplemental Table 2.1. Participants who responded yes to at least one of
the responses assigned to a barrier were categorized as having perceived that barrier in the past
12 months.
2.2.3 Independent Variable
Type of opioid misuse was assigned to all respondents who reported “time since last used
heroin” or “most recent pain reliever misuse” during the last 12 months and included three
categories: individuals who reported use of heroin only (HO, N=127), individuals who only
reported misuse of prescription pain relievers (PPR, N=5,580), and individuals who reported
misuse of both heroin and prescription pain relievers (H+PPR, N=388).
2.2.4 Covariates
The theoretical framework for this study was based on Ronald Anderson’s Behavioral
Model of Health Services Use.76,77 This model theorizes that an individual’s use of healthcare
services is a function of: the predisposition of the individual to use the services, an individual’s
ability to secure services; and the individual’s need for such services.76 Covariates chosen to
represent the predisposing, enabling, and need factors that make up Anderson’s model were
selected based on previous literature.12,78,79 Predisposing characteristics include “biological
imperatives” and social factors that represent family relationships and status in society.78
Predisposing characteristics included in the current study were age in years (18-25/26-34/3549/50-64), sex (male, female), race/ethnicity (Non-Hispanic White/Non-Hispanic Black or
African American/Non-Hispanic Asian/Hispanic/ other (including: Non-Hispanic native
American or AK native, Non-Hispanic native HI or other pacific islander, and non-Hispanic
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more than one race)), sexual identity (heterosexual/ lesbian, gay, or bisexual), and education
level (less high school or high school grad/some college, associates, or college graduate).
Enabling factors reflect financial and organizational factors that may enable service
utilization.78 These included: total family income (≤ $20,000/ >$20,000), urbanicity (large
metro/small metro/non-metro), insurance type (Medicaid/private/other (e.g., TRICARE,
CHAMPUS, CHAMPVA, VA, military, Medicare, or “covered by insurance-type other”)), and
survey year (2015/2016/2017).
The need factors embody the perceived need for health services and the evaluated need
(as diagnosed by a clinician). These included severe psychological distress as indicated by past
year psychological distress measured by the K6 scale (yes (≥13)/no(<13)), self-reported health
(excellent, very good, good/fair or poor), past year injection drug use (IDU) (yes/no), and
additional SUD. The K6 scale is a measure of how often a respondent experienced symptoms of
psychological distress (e.g., nervous, hopeless, restless, depressed, worthless, or run-down)
during the past 12 months.72 Those with a score of 13 or greater were classified as having severe
psychological distress in the past 12 months.
Additional SUD was the total sum of all of SUD reported by the individual. For example,
if an individual reported alcohol use disorder and cocaine use disorder, his/her number of
additional SUD would be 2. All SUD were logically assigned based on whether the respondent
met the criteria as defined in the fourth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV).72
2.2.5 Ethical Considerations
Any analysis of publicly available secondary data, where information is recorded by the
investigator in a manner that subjects cannot be identified (either directly or through identifiers)
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is considered exempt by the Virginia Commonwealth University School of Medicine
Institutional Review Board.80
2.2.6 Analytic Strategy
All data analyses were performed using SAS 9.4 (SAS Institute Inc, NC). Analyses
accounted for the complex survey design of the NSDUH, and pooling of data for three years was
accounted for by dividing the weight from 2017 data by three.72 Pearson Chi-square analyses
were calculated to evaluate the association between predisposing, enabling, and need
characteristics by type of opioid misuse. Bivariate logistic regression analyses were performed to
assess the unadjusted association between the type of opioid misuse and all theoretical covariates
with each of the perceived barriers to accessing SUD treatment (Supplemental Table 2.2).
Multivariate logistic regression models were used to assess the association between type of
opioid misuse and each perceived barrier, adjusting for all covariates (age, sex, race/ethnicity,
sexual identity, education level, total family income, urbanicity, insurance type, survey year,
self-reported health, severe psychological distress, past year IDU, and additional SUD).
2.3 Results
2.3.1 Study cohort
Table 2.1 reports the characteristics of the study population by type of past year opioid
misuse. The number of individuals from each survey year was evenly distributed, with 34.5%,
34.3% and 31.3% in 2015, 2016, and 2017, respectively. The overall population was
predominantly male (53.4%), white (69.6%), heterosexual (89.4%), and evenly distributed
among the four age groups. The majority of the population had some college or graduated from
college (62.6%), reported a total family income of less than $20,000 (78.4%), and lived in a large
metropolitan community (56.9%). Nearly two-thirds (64.0%) reported having private insurance,
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while just over a quarter reported having Medicaid (27.3%). Half reported having good/fair/poor
health (49.8%), nearly a third reported severe psychological distress (31.7%) and 12.3% reported
past year IDU. Although the majority of participants reported no additional SUD (67.7%), nearly
a third (32.3%) reported at least 1 additional SUD.
2.3.2 Sociodemographic characteristics by type of opioid misuse
The majority of the 6,095 insured adults reporting past year opioid misuse were PPR
users (91.6%), followed by H+PPR users (6.4%) and HO users (2.1%). The proportion of males
was significantly lower for PPR users (52.4%) compared to HO (67.4%) and H+PPR users
(64.5%). Some college education was significantly more prevalent among PPR users (63.8%)
compared to HO (44.2%) and H+PPR (51.1%) users, and the proportion earning less than
$20,000 was significantly higher in HO (56.4%) compared to PPR (20.0%) and H+PPR (33.6%)
users. In addition, two-thirds of PPR users (66.6%) were on private insurance, compared to only
a third of HO (33.7%) and H+PPR users (35.0%), and the proportion of PPR users on Medicaid
(24.8%) was nearly half that of HO (58.3%) and H+PPR (55.7%) users. The proportion of HO
reporting fair/poor health (71.9%) was significantly higher compared to PPR (48.9%) and
H+PPR (56.1%) users, and fewer PPR users reported severe psychological distress (30.4%), in
contrast to HO (42.5%) and H+PPR (49.1%) users. Further, past year IDU was significantly
more prevalent among HO (61.4%) and H+PPR (70.2%) users compared to PPR users (7.6%),
and the prevalence of 1 additional SUD (32.5%) or 3 additional SUDs (10.6%) were significantly
higher in H+PPR users as compared to HO (17.7%, 2.7%) and PPR users (22.9%, 2.1%).
The majority of the 244 respondents reporting at least one perceived barrier to accessing
treatment for SUD were PPR users (70.4%), followed by H+PPR users (25%), and HO users
(4.5%). Figure 2.1 illustrates the proportion of perceived barriers by type of opioid misuse
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among individuals reporting at least one perceived barrier. Half (50.5%) of the HO users
reported a financial barrier, followed by stigma-related barriers (39.8%), readiness barriers
(30.9%), and less than a quarter (23.4%) perceived a structural barrier. In contrast, PPR users
most often perceived readiness (45.5%) and structural (41.2%) barriers, followed by financial
(31.6%) and stigma-related (29.5%) barriers. Similar to the PPR group, the most perceived
barriers among H+PPR were readiness (50.9%) and structural (44.9%) barriers, while less than a
third reported financial (31.2%) and stigma-related barriers (30.6%).
2.3.4 Multivariable logistic regression of perceived barriers to treatment
2.3.4a Type of opioid misuse and perceived treatment barriers
Table 2.2 presents results from the multivariable logistic regression analysis of the
adjusted association between type of opioid misuse and four perceived berries to assessing
treatment. Type of opioid misuse was significantly associated with perceiving a readiness,
structural, and stigma related barrier. Compared to individuals who only reported misuse of PPR,
individuals reporting misuse of both H+PPR were at increased odds of perceiving a readiness
(aOR=2.80, 95% CI=1.08-7.27), structural (aOR=3.27, 95% CI=1.26-8.46), or stigma-related
(aOR=3.98, 95% CI=1.42-11.21) barrier to accessing treatment for SUD.
3.3.4b Covariates of interest associated with perceived barriers
Severe psychological distress. Individuals who reported severe psychological distress in
the past year (as indicated by the K6 scale score ≥ 13) had an increased likelihood of perceiving
all four barriers to accessing SUD treatment; reporting near triple the odds of perceiving a
readiness (aOR=3.02, 95% CI=1.55-5.90), financial (aOR=2.45, 95% CI=1.05-5.70), structural
(aOR=2.90, 95% CI=1.53-5.49), or stigma-related (aOR=2.90, 95% CI=1.42-5.92) barrier,
compared to those not reporting severe psychological distress in the past year.
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Additional SUD. Each additional SUD diagnoses increased the odds of perceiving a
readiness (aOR=1.60, 95% CI=1.29-1.98), financial (aOR=1.25, 95% CI=1.08-1.44, or structural
(aOR=1.34, 95% CI=1.11-1.62) barrier to accessing SUD treatment.
2.4 Discussion
Barriers to accessing treatment for SUD persist following nationwide implementation of
the ACA in 2014. Among individuals reporting past year opioid misuse, 3.7% reported
experiencing a barrier to accessing treatment for SUD. The findings of this study demonstrated
that the association between perceiving barriers to accessing treatment and type of opioid misuse
varied, and individuals reporting misuse of H+PPR during past year were more likely to perceive
readiness, structural, and stigma-related barriers to care as compared to those reporting misuse of
PPR only during the same period. Further, the results of this study identified two need
characteristics (additional SUD and severe psychological distress) that increased the likelihood
of perceiving each of the four barriers to accessing SUD treatment.
2.4.1 Misuse of H+PPR increased odds of experiencing readiness, structural, and stigma-related
barriers
While past studies have focused on the association between type of opioid misuse and
treatment outcomes,81–84 this is the first study to investigate the relationship between type of
opioid misuse and perceived barriers to accessing treatment for SUD. Misuse of H+PPR
significantly increased the odds of perceiving readiness, structural, and stigma-related barriers
compared to misuse of PPR only.
Readiness Barriers. Those misusing H+PPR had more than double the odds of perceiving
a readiness barrier compared to those reporting PPR misuse alone. Among all substance users,
perceived readiness to stop substance use is the most common reason for not engaging in
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treatment for SUD.85 In Baltimore, over two-thirds (69.6%) of opioid overdose survivors
reported not seeking treatment because they were not ready to stop substance use.85 This is
consistent with how individuals with OUD view their “need” for treatment; between 2015-2016
only 31.5% of individuals with OUD received treatment, and only 13.6% perceived the need for
such treatment.86 One possible explanation for the increased likelihood of readiness barriers in
H+PPR compared to PPR alone is the increased severity of OUD among the H+PPR group
compared to the PPR group. Studies report only 3.6-4.2% of individuals who misuse PPR start to
use heroin,87 suggesting that transitioning to heroin use appears to be part of the progression of
addiction in a subgroup of nonmedical users of PPR.87 Further, individuals with HO or H+PPR
addiction are more likely to engage in co-occurring substance use, and be diagnosed with SUD in
addition to OUD.83,88 Thus, it might be possible that the stronger addiction severity in the small
subgroup of H+PPR may influence their readiness to access SUD treatment. Very few studies
have investigated how type of opioid misuse may influence readiness barriers to accessing SUD
treatment. Future research should assess how type of substance use influences the reasons that
opioid users are not ready for treatment, to improve efforts to motivate these individuals to
engage in SUD treatment.
Structural Barriers. Individuals in the H+PPR group were three times more likely to
perceive a structural barrier compared to those with PPR misuse only. One potential explanation
for the increased odds of perceiving structural barriers is inadequate coverage for services; as
over half of the H+PPR group had Medicaid compared to the PPR group (55.7% vs. 24.8%).
However, although Medicaid recipients in the current study had an increased likelihood of
experiencing a structural barrier compared to those with private insurance, this relationship was
not statistically significant. This is surprising given the findings of previous studies, which
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reported that individuals with Medicaid were more likely to be turned away from care compared
to those with employer-sponsored coverage,89 and that SUD treatment facilities were not
adequately prepared for an influx of patients with Medicaid.60 However, the findings of the
current study should also not be used to fully dismiss inadequate coverage of SUD services as a
potential explanation, as the analysis could not account for the state-by-state differences in SUD
service coverage for Medicaid recipients.
In addition, it is also possible that the increased severity of addiction in the H+PPR group
would require more intensive SUD treatment that is often unavailable due to insurance
restrictions on SUD services. The American Society of Addiction Medicine report that patients
who engaged in co-occurring substance use might need additional supervision to consider
methadone or inpatient/residential SUD treatment for additional monitoring during withdrawal.90
Yet even after the implementation of the ACA these treatment options present challenges. For
example, methadone can only be legally prescribed to patients who are able to make daily visits
to an opiate treatment program, which limits accessibility to individuals who work or live in rural
areas far away from the treatment program.91 Further, these options may not be covered by
insurance, as many states restrict coverage of methadone and residential services for individuals
on Medicaid.60,92 The findings of the current study provide additional support for the findings of
previous researchers, who have concluded that implementation of the ACA has not altered the
tiered nature of health care access.89 State and local governments should work to decrease limits
placed on SUD treatment, and increase the number of facilities accepting Medicaid.
Stigma-related Barriers. Individuals in the H+PPR group had nearly four times the odds
of perceiving a stigma-related barrier compared to those reporting PPR misuse. Among
individuals with any type of SUD, 10-23% report stigma as a barrier to seeking SUD treatment,66
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reporting stigmatization from healthcare providers,65,66,93,94 family and friends, and self-stigma
(e.g., feelings of shame).66,93 Surprisingly, race/ethnicity and urbanicity, often reported as risk
factors for stigmatization, were not significantly different among the groups.95 One explanation
for the increased likelihood of H+PPR to perceive barriers due to stigma compared to the PPR
group may be related to the disproportionately high number of individuals who inject drugs in
the H+PPR group compared to the PPR group (70.2% vs. 7.6%). Individuals who inject drugs
often report negative interactions with healthcare professionals,96,97 reporting that injecting
carries a higher stigma than other methods of drug delivery like smoking or ingesting.98 Further,
studies show that clinicians often admit to stigma specifically concerning individuals who inject
drugs.99 Thus, the H+PPR group may feel more susceptible to privacy concerns while receiving
treatment, and consequently may want to avoid a daily visit that might draw negative attention
from others.95
It is difficult to assess the consistency of these findings with those of previous literature,
as no previous studies have explored the association between type of opioid misuse and
perceived stigma.
2.4.2: Covariates of interest associated with perceived barriers to accessing SUD treatment
Additional SUD. Each additional diagnosis of SUD increased the odds of experiencing
readiness, financial, and structural barriers. Between 77.2-93.3% of individuals with OUD report
an additional SUD,100,101 and previous literature shows how detrimental additional SUDs can be
on treatment outcomes, often increasing the risk of dropout.102–104 It is not surprising that those
with additional SUD are more likely to perceive a readiness barrier, as individuals with
additional SUD are less likely to seek out treatment or end current substance use compared to
individuals using opioids alone. In addition, as facilities are recommended to provide opioid-

24

misusing individuals with co-morbid SUD with an individualized approach, these findings may
indicate a continued demand for programs to meet this need.
Mental Health Severity. Mental health severity was the only characteristic that was
significantly associated with the increased likelihood of perceiving all four barriers to accessing
treatment for SUD. This is an important finding, as comorbid psychiatric disorders are highly
prevalent, reported in 64.3-68.4% of individuals with OUD100,105 and 78-78.5% of individuals
receiving treatment for OUD.103,106 These findings are supported by the results of previous
studies which report that individuals on Medicaid are less likely to receive SUD treatment. In
2014 a study of Medicaid clients with OUD found that those with severe mental disorders, such
as schizophrenia and/or bipolar were far less likely to receive medicated assisted treatment
compared to individuals without those diagnoses.107 These findings are also consistent with a
previous analysis using the NSDUH data from 2008-2014, in which a high proportion of
individuals with mild to serious mental illness and comorbid OUD reported not receiving needed
SUD treatment; with over half reporting a perceived barrier due to affordability, and close to a
third citing barriers due to stigma or lack of readiness.108 The consistency between the results of
the current study and previous literature may imply that changes following the ACA have not
completely addressed treatment access barriers specific to those with severe mental illness.
Further research is needed to understand how to address these barriers to help individuals with
comorbid mental illness successfully participate in SUD treatment.
2.4.3 Strengths and Limitations
The NSDUH is the nationally representative source of annual estimates of drug use and
mental illness among civilian members of the noninstitutionalized population in the United
States.109 This survey uses tools to assure privacy and confidentiality of all participant’s
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responses, to increase the likelihood of honest reporting of illicit drug use and illegal activities.
The response rate for each of the three years included here were relatively high, ranging between
69.7- 67.1%.110–112 In addition, this study was strengthened by the use of the Behavioral Model
of Health Services Use, making the findings easier to adapt to support the design of communitybased interventions that could address the disparities in accessing SUD treatment faced by the
OUD community.
These findings are also subject to several limitations. This survey is cross-sectional and
not longitudinal; inferences for individuals cannot be made over the three-year period and
direction of effect and causality cannot be determined. Additionally, questions about the use of
illegal substances may discourage participant’s candor, thus responses could be influenced by
social desirability bias. Further, responses may be subject to recall bias, as many questions
required participants to recall events taking place over the past 12 months.
The current study did not account for additional factors associated with stigma related
barriers to treatment, such as pregnancy, parenthood, marital status, and Human
Immunodeficiency Virus status. 21,66 Future investigation into this relationship should consider
inclusion of these factors to expand on the work of this analysis.
Interpretation of these findings are limited to individuals with additional SUD, and
should not be generalized to opioid-misusing individuals who may engage in the use of multiple
substances but do not have an additional SUD. Additional information on these individual’s
patterns of substance use may be beneficial to the development of interventions for increasing
treatment access. Future research should more accurately capture patterns of co-occurring
substance use in order to better understand the relationship between patterns of substance use and
perceived barriers to accessing SUD treatment.

26

Finally, generalizability of these findings are limited to the civilian, noninstitutionalized
population of the United States. Although this only excludes approximately 3% of the U.S.
population,114 it likely excludes several subgroups considered to be at increased risk for OUD,
including prisoners, military personnel, and the homeless. Additionally, the interview can only
be conducted in English and Spanish, which excludes all non-English and Spanish speakers.114
Exclusion of these groups may not only limits the generalizability of findings, but also result in
the underestimation of the true prevalence of less commonly used drugs, including heroin.114
2.5 Conclusions
This study highlighted that different types of opioid misuse could be associated with
perceived barriers to accessing treatment, and the association could be further impacted by
severe psychological distress and additional SUD. The shift in opioid misuse from PPR to heroin
and synthetic opioids has important implications for the development of effective treatment
strategies for individuals with SUD. Further work is needed to better understand how these
specific treatment barriers might influence type of opioid misuse.
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Chapter 3. The influence of patterns of polysubstance use on perceived barriers to
accessing treatment for substance use disorder
Abstract
Background: Opioid users engaging in polysubstance use (PSU) are at increased risk of
overdose and mortality, yet little is known about the relationship between PSU and barriers to
accessing substance use disorder (SUD) treatment. This study investigates the association
between PSU classes and perceived readiness, financial, structural, and stigma-related barriers to
accessing SUD treatment.
Methods: Data were included from the 2015-2017 National Survey on Drug Use and Health.
Latent Class Analysis (LCA) determined patterns of PSU in 6,095 insured adults reporting pastyear misuse of prescription pain relievers (PPR), heroin, or both. Multivariate logistic regression
assessed the relationship between PSU classes and perceived barriers to accessing SUD
treatment, adjusted for age, sex, race, sexual identity, education, total family income, urbanicity,
insurance, survey year, self-reported health, severe psychological distress, average daily cigarette
use, and accounting for complex survey design.
Results: LCA identified three patterns of past-year PSU: 1) Heroin injectors with high PSU
(n=473, 7.8%), 2) PPR users with low PSU (n=4,000, 26.6%), and 3) PPR users with high PSU
(n=1,622, 65.6%). Heroin injectors with high PSU faced significantly greater odds of perceiving
readiness (aOR=3.11, 95%CI=1.43-6.77), structural (aOR=2.42, 95%CI=1.22-4.79), and stigmarelated (aOR=3.13, 95%CI=1.31-7.48) barriers to accessing SUD treatment compared to PPR
users with low PSU.
Conclusions: These findings highlight a subpopulation of opioid users at increased odds of
perceiving readiness, structural, and stigma-related barriers to accessing SUD treatment.
Targeted public health efforts are necessary to decrease perceived barriers to accessing treatment
for SUD among opioid injecting individuals engaging in heavy PSU.
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3.1 Introduction
Polysubstance use (PSU) is often defined as the concurrent or simultaneous consumption
of more than one substance over a specified period of time.115 Many studies consider the
combined or subsequent use of both licit (alcohol, tobacco), and illicit (cocaine,
methamphetamines, marijuana, sedatives, etc.) substances as PSU. PSU is increasingly being
recognized as a problem by the public health community, due to increases in the number of
multi-drug combination deaths. Jones et. al reported an increase in the rate of benzodiazepine
involvement in opioid overdose deaths, from 18.0% in 2004 to 31.0% in 2011,116 and Kandel et
al., reported an increase in deaths resulting from a combination of prescription opioids with at
least one additional psychoactive substance (benzodiazepines, antidepressants, heroin, alcohol,
and cocaine) from 44.3% in 2002-2003 to 57.9% in 2014-2015.117 In addition, PSU increases an
individual’s risk of a variety of adverse health outcomes, including: psychopathology,118,119
chronic health conditions,118 risk-taking behaviors,119 criminal activity,120,121 and nonfatal
overdose.122–124
3.1.1 PSU use among opioid-misusing individuals
The increase in opioid-related fatalities over the past two decades may be partially
explained by deaths resulting from the combination of opioid use and PSU.117 Prevalence of PSU
among opioid-misusing individuals is fairly high. Approximately 53-89.6% of opioid-misusing
populations report PSU.122,125–127 Opioid-misusing individuals most often report the co-use of
tobacco,120,128 alcohol,129–133 cannabis,130,132,133 cocaine,122,127,131 benzodiazepines,130–132 and
methamphetamines127. While the high prevalence of PSU among opioid users may be due to an
increased likelihood of opioid use among individuals with substance use disorders (SUD) (e.g.
alcoholism, etc.), it is most likely due to the use of certain substances (i.e., cocaine,
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benzodiazepines, methamphetamines) to enhance opioid intoxication, or alleviate the symptoms
of opioid withdrawl.134–136
Opioid-misusing individuals with PSU are less responsive to treatment for SUD than
individuals without PSU disorders.120,137 Many opioid-misusing individuals entering SUD
treatment report co-occurring use of alcohol, marijuana, cocaine, and benzodiazepines,138,139 and
75-86.0% of individuals entering opiate treatment report tobacco use.140–142 Individuals
continuing PSU during SUD treatment are at increased risk of relapse143,144 and attrition.82,139,145–
147

Further, co-occurring PSU can significantly increase the likelihood of mortality during

treatment; Ries et al. reported that the majority of deaths occurring during methadone treatments
are attributed to polysubstance overdoses,128 and Lofwall et al. reported buprenorphine-related
deaths most often occurred due to the concomitant use of central nervous system
depressants.128,148
Currently, the opioid-agonist methadone demonstrates the most comprehensive evidence
of efficacy in individuals with co-occurring SUDs.149 Studies investigating outcomes of
methadone administration report statistically significant decreases in PSU following
treatment.150–152 In addition, in 2015 Ries et al. reported that individuals with Opioid Use
Disorder (OUD) and PSU dependence could be effectively managed in an inpatient facility that
offers 24-hour medical monitoring.128 Nevertheless, individuals engaged in PSU have the lowest
likelihood of opioid treatment success.
3.1.2 Barriers to accessing treatment for polysubstance users
Compared to studies of opioid treatment outcomes, there are few that investigate the
association between PSU and opioid treatment enrollment and detail the role of barriers to
seeking such care. Previous studies suggest that individuals engaged in opioid use and PSU
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actively seek treatment for emergency and behavioral health services125. For example, Calcaterra
et. al. reported significantly higher incidence rate ratios for opioid users and individuals reporting
multiple drug use accessing behavioral and emergent health care compared to those reporting no
drug use125. Yet few studies detail how engagement and treatment seeking behaviors might differ
between those using opioids and those engaging in PSU.
Opioid users with PSU are likely to experience barriers to accessing opiate treatment
programs. This could be due to lingering guidelines of past programs, where continued use of
additional substances during opiate treatment programs was considered grounds for dismissal
from treatment. Although the Federal Drug Administration advised against the removal of
patients engaging in PSU from treatment in 2017, stating that the harm caused by untreated
opioid addiction could outweigh the risks of serious side effects from PSU.153
Despite this recommendation, individuals with PSU may still face structural barriers to
accessing the most appropriate treatment for their needs. However, state and Federal control over
these types of opioid treatment decrease their accessibility. Methadone remains the most
restricted OUD medication in the US,154 which may pose structural barriers to individuals
seeking treatment. Moreover, inpatient SUD programs are the least likely to be funded by private
insurance and Medicaid, creating financial deterrents to seeking treatment. Although addressing
these barriers is crucial to make SUD treatment available to opioid users, to date no study has
examined the barriers to accessing opioid treatment faced by individuals engaging in PSU.
3.1.3 Issues defining PSU
Examining treatment outcomes in the context of polysubstance or polydrug use is
difficult, as it can involve a variety of licit and illicit substance configurations, making it
challenging to identify salient categories.155 As there is currently no standardized way to account
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for PSU, studies use a variation of definitions, such as “multiple drugs at the same time” ,156 or
“summing the total number of substances used”,157 while other studies provided no explanation
for how PSU was defined.144,158–160 Due to the variety of configurations for the types and
frequency of substance use, it is not possible to directly observe “patterns” of polysubstance use,
but these patterns may be determined through the observation of related variables.161 One method
used to identify substance use patterns is latent class analysis (LCA),162 which can define a
hidden or “latent” variable within which the manifest variables are locally independent.162 In
other words, if “polysubstance use” can be defined as a latent variable, then the classes of
polysubstance use are taken to represent latent types of the polysubstance use as defined by
measures of substance use within the sampled population. Identification of the polysubstance use
latent variable could enable a better understanding of the socio-demographic and clinical
differences between substance—using subgroups, and how perceived barriers to accessing
treatment for SUD may differ among these substance-using subgroups.163
Previous studies have used LCA to identify patterns of substance use based on the
substances used,115,120,132,155,164–169 or routes of substance administration.123,170–174 Previous LCA
have examined the relationship between PSU classes and a variety of health-related outcomes,
including: risky drug use behaviors,155,167,172 Human-immunodeficiency virus (HIV) risk
behaviors,123,170,173 psychological distress,167 recent overdose,174 and mortality,165 however only
two studies explored the differences in healthcare utilization and treatment.120,155 In 2018,
Lorvick et al. reported that among women using ‘hard drugs’ – cocaine, methamphetamines, or
heroin – the heavy polydrug class had significantly higher odds of unmet physical and mental
healthcare needs.155 These findings highlight the importance of identifying barriers that may
keep individuals with PSU from accessing care.
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One large limitation of previous LCA characterizing patterns of PSU is a lack of
generalizability, either due to the choice of population or limited inclusion of substances
included in the LCA. Of the 8 previous LCA which reported patterns of PSU among opioid
users,123,132,164,165,171,173,174 only 2 use a population from the United States.164,171 Yet the patterns
of PSU among these populations are likely different to what would be observed in a nationwide
population of opioid users. For instance, Kuramoto et al. performed an LCA using responses
from participants reporting weekly use of heroin or cocaine in a large U.S. city,171 and Bobashev
et al. recruited heroin-using individuals from a syringe exchange program in a large U.S. city.164
Previous LCA are further limited in the information they provide due to variation in the
substances chosen for inclusion in the LCA. Among the LCA in opioid-misusing populations,
substances most often included were methamphetamines, marijuana, cocaine, and
heroin.123,132,164,165,171,175 Only half (50.0%) included misuse of prescription pain relievers
(PPR)/prescription opioids and alcohol.123,164,165,175 Very few studies included the use of
benzodiazepines, barbiturates, crack, hallucinogens, ketamine, power cocaine, speedball,
stimulants, tranquilizers, and inhalants.123,132,171,175 The aforementioned limitations of previous
LCA highlight gaps which may limit accurate characterization of PSU patterns, and support the
need for an additional LCA to characterize patterns of PSU in a nationwide sample of opioidmisusing individuals.
The lack of consensus of the definition of PSU among opioid users limits the
generalizability of previous studies that identify the barriers to seeking opioid treatment.
Additionally, although past research has indicated poorer treatment engagement among
polysubstance users, no study has yet examined the relationship between patterns of substance
use and barriers to accessing treatment for SUD among opioid-misusing individuals. The
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objectives of this study were twofold: 1) identify patterns of past year PSU among a nationally
representative sample of opioid-misusing adults in the U.S., and 2) evaluate the association
between membership in PSU classes and perceived readiness, financial, structural, and stigmarelated barriers to accessing treatment for SUD.
3.2 Methods
3.2.1 Data Source and Study Design
This study utilized data from the 2015-2017 National Survey on Drug Use and Health
(NSDUH), a survey sponsored by the Substance Abuse and Mental Health Services
Administration, within the U.S. Department of Health and Human Services.176 The survey is
administered to the non-institutionalized civilian population aged 12 and older, collecting
detailed information on the use of alcohol, illicit drugs, mental illness, SUDs, utilization of
behavioral health treatments, and treatment barriers for behavioral health conditions and
treatments.73
The NSDUH uses a stratified multistage area probability sample designed to represent
each of the 50 States and the District of Columbia. Each sampled individual was scheduled for a
60-minute interview conducted in a private area of the home on a laptop provided by the field
investigator. To increase cooperation and honest reporting about sensitive topics, the NSDUH
employs methodological practices aimed at increasing the accuracy of self-reports, using a
combination of computer-assisted personal interviewing and audio computer-assisted selfinterviewing, and by providing assurances that individual responses will remain confidential.177
Upon completion of a full interview, each respondent is given $30.178
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3.2.2 Study Population
Similar to Chapter 2, this study used publicly available data from the NSDUH from 2015-2017,
which represents the period after the Patient Protection and Affordable Care Act (ACA) was
implemented throughout the U.S. Inclusion in this study was also limited to insured adults
between the ages of 18-64, who reported past year use of heroin, past year misuse of PPR, or
both.
3.2.3 Measures
Past year Substance Use. Indicator variables included in the LCA model were binary
indicators for the past year use of 12 substances (based on the question “Most recent use of
[substance]), and binary measures reporting past year injection of substances (based on the
question: “Time since last used needle to inject [substance]?”).
The substances assessed included: binge alcohol use, (defined as drinking 5 or more
drinks on the same occasion for males and four or more drinks on the same occasion for
females), crack, cocaine, hallucinogens (LSD, PCP, Ecstasy, DMT/AMT/Foxy, Ketamine, and
Salvia), heroin, inhalants, methamphetamines, marijuana, PPR, sedatives, stimulants, and
tranquilizers. Injection of four substances was also assessed, including: cocaine, heroin,
methamphetamines, or “other” substances.
Binge alcohol use was selected to distinguish between less harmful occasional alcohol
use and more problematic binge drinking. As a recent study reported that the prevalence of
opioid misuse increases with the frequency of binge drinking,179 it is reasonable to expect that
binge drinking adults would be at greater risk for an overdose due to an interaction between
alcohol and opioids.
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All substances selected for inclusion in the current LCA were also included in previous
studies for classifying subtypes of PSU. Surprisingly, of the 8 previous studies characterizing
PSU in opioid-misusing populations, none included tobacco use as an indicator variable, despite
the high prevalence of tobacco use among opioid users.128 This is likely because the high
prevalence of tobacco use among opioid-users would not be a distinguishing factor between
classes. To ensure comparison of our classes to classes of other studies, tobacco use was not
included as an indicator variable in the LCA, but instead was accounted for in the final
regression analyses.
Use of PPR, stimulants, tranquilizers, and sedatives were only included if the respondent
indicated past year misuse, defined as: Use of [medication] in a way the doctor did not direct,
including: using it without a prescription, using it in greater amounts, more often, or longer, or
using it in any other way a doctor did not direct.178 These categories are created by the NSDUH
to represent a combination of prescriptions commonly misused. Further information on
substances included in the prescription drug categories is available in Supplemental Table 3.1.
Sociodemographic Variables. Covariates were selected to match the model previously
described in Chapter 2, and included; sex (male/female), age (18-25/26-34/35-64), race/ethnicity
(Non-Hispanic White/Non-Hispanic Black, African American/Non-Hispanic
Asian/Hispanic/Other), sexual identity (heterosexual/lesbian, gay, or bisexual), education level
(less high school or high school grad/some college, associates, or college graduate), total family
income (≤ $20,000/ >$20,000), urbanicity (large metro/small metro/non-metro), type of health
insurance (Medicaid/Private/ other (e.g., TRICARE, CHAMPUS, CHAMPVA, VA, military,
Medicare, or “covered by insurance-type other”)), survey year (2015/2016/2017), severe
psychological distress as indicated by the K6 scale (yes (≥13)/no(<13)), self-reported physical
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health (excellent, very good, good/fair or poor), past year tobacco use (defined as any reported
past year use of cigarettes, cigars, pipes, or smokeless tobacco), and average number of cigarettes
used per week (≥1-1 per day/2 to 5 per day/6 to 15 per day/16 to > 35 per day).
Barriers to SUD Treatment. The dependent variables for this study were perceived
readiness, financial, structural, or stigma-related barriers to accessing initial or additional
treatment for SUD within the past 12 months. Additional information on these barriers was
previously described in Chapter 2, and is also available in Supplemental Table 2.1. Data were
collected from 11 responses to create the four dichotomous barrier variables (yes/no), as
demonstrated in previous studies.29,37,73 Respondents who said yes to one or more of the
statements asked in any group were categorized as having perceived that barrier in the past 12
months.
3.2.4 Statistical Analysis
LCA were conducted using Mplus 7.4, and multivariate regression analyses were
conducted using SAS 9.4. The statistical analysis for this project occurred in three steps: 1) LCA
was used to identify distinct classes of polysubstance use based on the unweighted frequency of
past year substance use in the population, 2) individual cases were assigned to each class of
polysubstance use, and 3) multivariate logistic regression was used to assess the association
between predicted polysubstance class membership and perceived barriers to accessing treatment
for substance use disorder.
Step 1: Latent Class Analysis. LCA was utilized to identify hidden subpopulations of
PSU that reflected distinct subgroups of substance use in a population of opioid-misusing
individuals. LCA is unique from other “mixture model” types of cluster analysis as it is intended
for use with categorical data.180 This is likely one of the reasons so many researchers have used
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LCA to describe PSU, as substance use is typically measured at the categorical level.180 The
LCA model posits the existence of two or more unobservable population subtypes, or latent
classes.180 A latent variable is measured indirectly by means of two or more observed variables
within a population.163 Figure 3.1 illustrates a hypothetical latent variable. In Figure 3.1 an oval
represents the latent variable, three squares (X1, X2, X3) represent the observed indicator
variables used to measure the latent variable, and three circles (e1, e2, e3) represent the error
component associated with each indicator variable. Note the arrows in this diagram show the
causal flow stems from the latent variable to the indicator variable; this illustrates the concept
that observed indicator variables measure latent variables, but they do not cause the latent
variable.163
In LCA the latent variable is categorical, or made up of classes, and each class has a set
of probabilities for various responses to each indicator variable. The first equation in latent class
modeling expresses the probability of observing response pattern y defined by:
C

P(Y=y) =

Σ

c=1

p (X=c) x p(Y=y/X=c)

X represents the categorical latent variable, c is a specific latent class among C classes, y is the
realization of the vector Y measuring the response patterns (X Y), p(X=c) represents the latent
class probability, or the probability of belonging to class c, and p(Y=y/X=c) is the conditional
response probability, or the conditional probability of having response pattern y, given that X belongs
to specific class c.181 To illustrate, Figure 3.2 provides a schematic representation of a 3 class model.
In Figure 3.2, the circle at top represents a case selected from the population at random, X represents
latent classes 1-3, and Sx are three indicator variables. The probability of being in latent class 1 is
represented by p(X=1), and p(Y=1/X=1) is the conditional probability of reporting indicator 1 for
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latent class 1. For example, if p(X=1) = 0.4 and p(Y=1/X=1) = 0.2, then an individual chosen at
random would have a 40% chance of belonging to latent class 1, and a 20% chance of reporting
indicator 1 given membership in latent class 1.
In the current study, LCA was performed using 16 indicators, which reported the unweighted
prevalence of past-year substance use for: binge alcohol use, crack, cocaine, hallucinogens, heroin,
inhalants, methamphetamines, marijuana, PPR, sedatives, stimulants, tranquilizers, and routes of
substance administration (use of a needle to inject methamphetamines, cocaine, heroin, or other
drugs).
An important assumption of the LCA model is the assumption of local independence, or that
conditional on the latent variable, the observed variables are independent.163 This assumption is
visually represented in Figure 3.1; which shows that each indicator variable is a function of the latent
variable and an error term, and only connected through the latent variable. Thus, if each indicator
conditioning on the latent variable is independent, then the joint probability of all the elements making
up the y vector for latent class c can be found by multiplying the individual probability parameters
corresponding to a particular latent class. This leads to the second equation for LCA, which expresses
the probability of observing the response pattern as a function of the latent class probabilities and the
conditional response probabilities.
C

P(Y=y) =

Σ

c=1

K

p (X=c) x

Π

k=1

p(Yk=yk/X=c)

In this equation, K represents the number of mutually independent indicator variables given the
class, and the parameters of this model can be estimated through implementation of a maximum
likelihood method.
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Step 2: Case assignment to latent classes. Membership in a latent class is determined
through an individual’s posterior probability of belonging to class c given observed response
pattern y. Posterior probabilities can be derived using Bayes’ theorem:
P(X=c/Y=y) = p(Y=y/X=c) x p(X=c)
p(Y=y)
Here, posterior probabilities are the product of the latent class probability p(X=c) and the
conditional response probability p(Y=y/X=c) over the probability of a particular response pattern
p(Y=y). Using posterior probabilities, cases are assigned to classes of the latent variable using
modal assignment, where each case is assigned to the class with the largest posterior probability.
Modal assignment is optimal, as it produces the smallest classification errors,181 and is
particularly beneficial in instances where there may be little or no information in the item
response probabilities. In the context of the current study, the probability of PPR misuse alone
would be expected to contribute little to class assignment, due to the high prevalence in the
population, thus membership would be expected to rely more heavily on the latent class
probability.
Assessing LCA model fitness. The latent class model will be performed for multiple
classes, thus it is important to choose the model which has the best empirical fit. As there is
currently no standardized way to assess LCA model fitness, researchers suggest using a variety
of statistical indicators to determine fitness. The current study utilized four evaluative indicators
to determine which number of classes best fit the model, including: Sample-size adjusted
Bayesian Information Criterion (BICSS), entropy, Lo-Mendell-Rubin likelihood ratio test (LRT),
and the parametric bootstrapped likelihood ratio test (BLRT).
Even using an optimal method for assigning class membership, it is possible that some
individuals may be assigned to the wrong class. For this reason, it is important to assess the
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separation between the classes, or how well the classes can be distinguished based on existing
empirical information.181 This can be done by measuring how much membership of posterior
probabilities deviate from uniform using entropy, a standardized measure of the accuracy of
placing participants into classes based on their model-based posterior probabilities.163,182 Values
for entropy range from 0 – 1, and larger values indicate better latent class separation and
subsequently lower class error.
The sample size adjusted Bayesian Information Criterion was created to aid model
selection by penalizing the number of factors in a model.163,183 Models with the lowest BICSS are
considered to have the best fit.182 The LRT and BLRT are used to compare nested latent class
models. LRT uses an approximation to the likelihood ratio test distribution, and BLRT also uses
a likelihood-based technique, p-values for both tests can be used to compare the increase in
model fit between the k-1 and k class models.183,184
Step 3: Multivariate regression analysis. After determining the model with the best
empirical fit, results of the LCA were exported to SAS 9.4. Chi-square analyses were used to
determine differences in sociodemographic characteristics by class. Association between the
PSU classes and each of the perceived barriers to accessing treatment for SUD (readiness,
financial, structural, stigma-related) were assessed using multivariate logistic regression,
adjusting for age, sex, race/ethnicity, sexual identity, education level, total family income,
urbanicity, insurance type, survey year, self-reported health, severe psychological distress, and
average cigarette use per day. All SAS analyses accounted for the complex sampling design of
the NSDUH. Evaluative indicators used to assess regression model fit included the Log
Likelihood (LL), Akaike Information Criterion (AIC), and adjusted R2.
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3.3 Results
3.3.1 Study Cohort
There were 6,095 insured respondents reporting past year opioid misuse. The cohort was
evenly distributed among the age groups, with 26.0% aged 18-25, 24.1% aged 26-34, 27.9%
aged 35-49, and 22.1% aged 50-64. Respondents were predominantly male (53.4%), white
(69.6%), and heterosexual (89.4%), with some college or a college degree (62.3%), a total family
income above $20,000 (78.4%), and lived in a large metro area (56.9%). The majority reported
having private insurance (64.0%), over a quarter reported Medicaid (27.3%). Half of the
respondents reported very good/excellent health (50.2%), yet nearly a third reported severe
psychological distress occurring within the past year (31.7%).
The majority of respondents reported past year misuse of PPR (97.5%), far fewer
reported heroin use (8.4%). The majority of respondents reported use of tobacco (60.8%), while
nearly half reported binge alcohol and marijuana use (53.1% and 56.4%, respectively).
Tranquilizers were the second most often misused prescription medication (26.8%), followed by
stimulants (20.4%), while few respondents reported misuse of sedatives (5.6%). Cocaine was the
most often reported illicit substance (18.0%), followed by hallucinogens (16.0%), while very few
reported past year misuse of methamphetamines (6.3%), crack (3.6%), and inhalants (4.0%).
Approximately 12.3% of the sample reported any type of injection drug use within the past year,
Heroin injection occurred most frequently (4.5%), followed by injection of other drugs (2.6%),
methamphetamines (2.3%), and cocaine (1.6%).
3.3.2 Number of Classes
Fit statistics for classes 2-6 are described in Table 3.1. The three-class model was
selected based on high entropy (0.837), and significant p-values from both the LMR and the
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BLRT. The 3-class model was also deemed preferable to the 4-class model due to ease of class
interpretability and theoretical considerations.
3.3.3 Characteristics of the three-class model
Table 3.2 reports the response probabilities for endorsing each type of substance use,
categorized by most likely class membership for a three-class model, and Figure 3.3 illustrates
the latent classes of past year PSU. Class 1 was deemed the “Heroin injectors with high PSU”, as
individuals in this class had the highest probability of reporting illicit (heroin (89.5%), cocaine
(54.4%), crack (33.3%), methamphetamines (37.0%)) and injection (cocaine (19.1%), heroin
(57.3%), methamphetamines (27.6%), and other (29.7%)) substance use compared to other
classes.
Class 2 (“PPR users with low PSU”) contained the largest proportion of the study sample
(n=4000, 64.2%), and was composed of individuals reporting misuse of PPR (99.4%), who
reported moderate use of licit/near licit substances (binge alcohol (42.6%), marijuana (37.5%)),
low use of illicit substances, and almost no injection substance use.
Class 3 (27.9% of the sample) was the “PPR with high PSU” class, made up of
individuals misusing PPR (99.8%) who also reported disproportionately high misuse of
prescription medications (tranquilizers (52.6%), stimulants (50.2%)), licit/near licit substances
(binge alcohol use (80.9%), marijuana (95.6%)), and several illicit substances (cocaine (46.6%),
hallucinogens (47.8%)), but little to no injection substance use.
3.3.4 Comparison of sociodemographic characteristics by latent class membership
Table 3.3 reports sociodemographic characteristics of the study population by type of
latent class PSU. The age distribution was significantly different in each class. Heroin injectors
with high PSU were closer to middle age, with 33.5% between 26-34 and 26.5% between 35-49,
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while the PPR users with high PSU had a higher proportion of older individuals, with 26.5%
between 50-64 and 32.0% between 35-49. In contrast, the PPR users with low PSU had a
disproportionately higher prevalence of younger respondents, as 51.7% reported being 18-25. In
addition, while males were more prevalent among the Heroin injectors with high PSU (65.9%)
and PPR users with high PSU (64.2%), females made up over half (51.1%) of the PPR users
with low PSU.
PPR users with low PSU and PPR users with high PSU appeared to be similar with
respect to education level, total family income, and insurance type. Individuals in these classes
were more likely to have some college (64.0%, 63.1%), report a total family income of more
than $20,000 (81.6%, 75.7%), and were insured by private insurance (65.9%, 69.7%). In
contrast, Heroin injectors with high PSU were more likely to have a lower education (51.9%),
and make less than $20,000 (44.2%). Further, Heroin injectors with high PSU were far more
likely to be Medicaid recipients (59.1%).
3.3.5 Association between latent class membership and barriers to accessing treatment for SUD
Table 3.4 reports the adjusted odds of perceiving a barrier to SUD treatment for each
PSU class (odds ratios for all covariates provided in Supplemental Table 3.2). Compared to PPR
users with low PSU, readiness barriers were significantly more likely to be perceived by both
PPR users with high PSU (aOR=2.89, 95%CI=1.41-5.93) and Heroin injectors with high PSU
(aOR=3.11, 95%CI=1.43-6.77). Additionally, Heroin injectors with high PSU also had
significantly increased odds of perceiving structural (aOR=2.42, 95%CI=1.22-4.79) and stigmarelated barriers (aOR=3.13, 95%CI=1.31-7.48) compared to PPR users with low PSU.
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3.4 Discussion
The findings of this study identified three distinct classes of PSU within a nationally
representative sample of individuals reporting opioid misuse in the past year: (1) Heroin
injectors with high PSU, (2) PPR users with low PSU and (3) PPR users with high PSU. The
type of substances most often misused varied by class: whereas PPR users with low PSU only
reported a high probability of PPR misuse, PPR users with high PSU were characterized by high
probabilities of licit/near licit (binge alcohol and marijuana) and prescription drug misuse
(tranquilizers, stimulants). In contrast, Heroin injectors with high PSU reported high
probabilities of illicit (cocaine, crack, methamphetamines) and injection substance use, and
moderate probabilities of licit/near licit (binge alcohol, marijuana) and prescription misuse (PPR
tranquilizers, stimulants, and sedatives). The likelihood of perceiving barriers to accessing SUD
treatment also varied between PSU classes. Compared to the PPR users with low PSU, both the
Heroin injectors with high PSU and PPR users with high PSU class had significantly greater
odds of perceiving a readiness barrier. Heroin injectors with high PSU also reported significantly
increased odds of perceiving structural and stigma-related barriers to accessing SUD treatment.
The findings of this study highlight how barriers to accessing SUD treatment differ by distinct
PSU subgroups within the opioid-misusing population, and may require appropriately targeted
interventions to help decrease barriers to accessing treatment for SUD.
3.4.1 Differences between classes
The classes of PSU in this study may differ from those of previous LCA for a variety of
reasons. First, this study is unique as it provides patterns of PSU among opioid-misusing
individuals in the U.S. In contrast to previous studies, which investigated patterns of PSU among
heroin users,164,171 the current study reports patterns of PSU among individuals reporting past
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year use of heroin, PPR misuse, or both. Further, the patterns of PSU are likely different as this
study uses a nationally representative sample. This is different from previous studies, which
recruited people who inject drugs (PWID),166,168,185,186 or recruited from only one urban city,
where the increased availability of certain substances (i.e., methamphetamines, cocaine) might
have influenced the observed patterns of PSU, but not be reflective of substance use trends
throughout the nation168.
Previous U.S. studies have investigated the associations between patterns of PSU and
various health-related outcomes, including: healthcare utilization,155 overdose training,185 risk
behaviors (e.g., injection practices, sex risk behaviors, HIV/Hepatitis-C (HCV) risk
factors),123,155,167,170,172,173 psychological distress,167 drug overdose,186 and mortality.165 This study
is unique in that it examines the relationship between patterns of PSU and perceived barriers to
accessing treatment for SUD, which may provide insight into what obstacles continue to persist,
and which populations are most likely impacted. In addition, only one other U.S. study has
investigated the association between insurance status and class of PSU; reporting a high
prevalence (83%) of health insurance among a group of polysubstance using women, and no
significant differences in the prevalence of health insurance by classes of PSU.155 The findings of
the current study go further by identifying significant differences in types of insurance by classes
of PSU; Heroin injectors with high PSU contained the highest proportion of Medicaid recipients,
while private insurance was highly prevalent among PPR users with high PSU and PPR users
with low PSU. The high prevalence of Medicaid recipients in the Heroin injectors with high PSU
class relative to the other classes is consistent with the findings of previous literature, which
show a high prevalence of heroin use or dependence among individuals with Medicaid.187
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Understanding how type of insurance differs by class of PSU may further inform the discussion
of how to decrease barriers to accessing SUD treatment, as discussed in more detail below.
3.4.2 Substances of interest
Binge Alcohol Use. Conditional probabilities for binge alcohol use were highest for PPR
users with high PSU (80.9%). Previous studies have also reported the highest probabilities of
binge alcohol use in classes characterized by heavy PSU. Lorvick et al. found that binge drinking
was significantly higher in a “heavy polydrug class” where ≥ 75% of members reported use of
heroin, crack, non-heroin opioids, and benzodiazepines, with moderate use of cocaine and
methamphetamines.155 In addition, in an analysis of PSU among lifetime cocaine users, the
highest probabilities of binge drinking were reported in a class with high probabilities of
marijuana, prescription opioid, stimulant, and sedative misuse.188
The comparably low probability of binge alcohol use among Heroin injectors with high
PSU is also consistent with the results of previous studies, where the lowest conditional
probabilities of alcohol use were reported in classes characterized by heroin injectors.170,171 Yet,
while in the findings of the current study binge drinking appears to be lower among Heroin
injectors with high PSU, research suggests co-occurring alcohol use is becoming more prevalent
among heroin users. A 2015-2016 analysis assessing combinations of substance use among
heroin users reported alcohol as one of the most simultaneously co-used substances with both
heroin and prescription drugs.164 Further, a study of heroin and cocaine users in a methadonemaintenance program reported that drinking alcohol was associated with heroin craving and use
of other drugs.189 The moderate to high prevalence of binge alcohol use within each class
highlights the importance of screening for alcohol use in all opioid-misusing individuals entering
treatment for SUD, so that they may receive services best tailored to their needs.
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Marijuana Use. The probability of past year marijuana use was relatively high for Heroin
injectors with high PSU (71.3%) and PPR users with high PSU (95.6%). High probability of
marijuana use among heroin users was expected based on the results of previous studies. Past
month marijuana use was reported by 40-61.0% of PWID in the U.S.,155,164,185 and one analysis
of heroin users in Cleveland, OH reported that marijuana was one of the most common
simultaneously co-used substances with heroin.164 Previous studies in the U.S. have reported
high probabilities of marijuana use among individuals who report both illicit drug and
prescription opioid misuse,170,171,185,188 and two Canadian studies reported conditional
probabilities of marijuana use ≥ 50% within all classes of opioid users.132,175
Although the prevalence of marijuana use among PPR users with low PSU is comparably
low (37.5%), it is noteworthy that marijuana is one of two substances of moderate use in the
class containing the largest proportion of the population. This may be due to the rise in clinical
evidence supporting the use of marijuana to treat opioid withdrawal, reduce opioid use/misuse,
and improve outcomes for SUD treatment.190 Although findings of the current study show
marijuana use is most prevalent among Heroin injectors with high PSU and PPR users with high
PSU, future research should continue to monitor these patterns as legislation to decriminalize and
legalize recreational use spread throughout the U.S.
Tobacco use. Moreover, the findings of the current study are consistent with the
conclusions of previous studies, which stated that while smoking has decreased in the overall
population, it remains highly prevalent among opioid-misusing individuals.128 It is possible that
SUD treatment facilities may continue to avoid addressing nicotine dependence, believing it may
cause additional stress for patients. Yet studies have demonstrated that smoking cessation can be
effectively carried out during methadone maintenance,128 and one systematic review concluded
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that implementation of a smoking cessation intervention during SUD treatment often had no
significant impact on opioid or illicit drug use.191 Although the American Society of Addiction
Medicine recommends a tobacco use query and cessation counseling be performed during the
diagnosis of OUD, they also state that further research on tobacco cessation during opiate
treatment programs is needed before specific evidence-based recommendations can be made.90
The high prevalence of tobacco use among these groups highlights the necessity of investigating
tobacco use in these patients, in order to monitor and reduce use within this population.
Surveillance of tobacco use among opioid-users could better inform the development and
evaluation of interventions promoting smoking cessation. Future research should consider
accounting for tobacco use when assessing patterns of substance use among opioid-misusing
populations.
3.4.3 Association between classes of PSU and barriers to accessing treatment for SUD
Readiness Barriers. The Heroin injectors with high PSU and PPR users with high PSU
were significantly more likely to perceive a readiness barrier to treatment compared to PPR users
with low PSU. These findings are consistent with those of earlier studies reporting readiness and
motivation to stop using opioids as a persisting issue. Over a third of opioid misusing adults
throughout the U.S. report they are not yet ready to stop using opioids.86 Among PWID, not
being ready for treatment, and not viewing drug use as a problem are common reasons for not
seeking treatment for SUD.192 Education and targeted interventions to connect opioid-misusing
individuals with treatment are crucial in order to increase enrollment in SUD treatment. By
identifying distinct groups of opioid users with a high likelihood of perceiving readiness barriers
(PPR users with high PSU and Heroin users with high PSU) the findings of this study could be
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used to develop more targeted interventions that can be implemented in areas frequented by these
high-risk populations.
Structural Barriers. The heroin injectors with high PSU were nearly two and a half times
more likely to perceive a structural barrier to treatment in comparison to PPR users with low
PSU. One likely explanation is that heroin injectors with high PSU are more likely to be covered
by Medicaid, as over half (59.1%) were Medicaid recipients, and as such may be more likely to
experience coverage-related barriers to treatment access. Although Medicaid coverage has
increased substantially among individuals with SUD following the implementation of the ACA,
the supply of SUD treatment available to Medicaid covered individuals has not kept pace.21,38
This is likely because many states’ Medicaid programs restrict coverage of addiction treatment;
requiring prior authorization for medications used to treat opioid addiction or imposing lifetime
treatment caps that limit accessibility.193,194 In addition, poor reimbursement rates in comparison
to private insurance may lead to decreased acceptance of Medicaid among SUD treatment
providers; between 2014-2017, only 52.0% of buprenorphine-prescribing physicians accepted
Medicaid for buprenorphine-related office visits,194 and Saloner et al. found that opioid addiction
treatment utilization was nearly 30% higher among Medicaid enrollees in states where Medicaid
reimbursed methadone, compared to states with no public funding for methadone.195 Further
research is needed to better understand the relationship between perceived barriers and SUD
treatment Medicaid coverage policies.
In addition, Heroin injectors with high PSU may face more barriers finding appropriate
treatment. PWID often report medical196 and psychiatric197 comorbidities that may complicate
their ability to find treatment for SUD. Although policies such as prescription guidelines and
prescription monitoring programs may have contributed to the rise in PWID, treatment coverage
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for PWID in the U.S. continues to be far below international standards, as the ratio between the
availability of treatment services and the number of PWID who could use those services remains
low.198 In addition, resources to address psychiatric comorbidity during treatment for SUD are
often limited.199 One study assessing addiction treatment programs between 2004-2011 found
only 18% were capable of dual diagnosis of addiction and mental health treatment.200 Taken
together, these findings emphasize that additional work is needed to decrease structural barriers
that prevent individuals with high heroin, PSU and injection substance use from accessing
treatment for SUD.
Stigma-Related Barriers. Heroin injectors with high PSU had three times the odds of
experiencing a stigma-related barrier compared to PPR users with low PSU. Whereas noninjecting individuals who misuse PPR may be able to conceal their addiction, PWID are more
likely to bear physical symptoms (i.e., open sores, “track marks”) or comorbidities (i.e., HIV,
HCV, Endocarditis) that reveal their addiction. Many PWID report experiencing stigma due to
family, community, and healthcare professionals.201 Negative interactions with healthcare
providers are a leading reason PWID are hesitant to access SUD treatment.96,97 In one study,
PWID perceived attitudes from healthcare professionals that were based solely on their
knowledge of the participants’ injection drug use, stating that they felt “looked down on” by
medical personnel, and reporting that medical staff often prioritized care for others, placing
PWID “at the back of the line”.97 In addition, clinician attitudes towards PWID could influence
quality of care. Medical staff report that their colleagues are less supportive of harm reduction
services for PWID,202 and a significant predictor of support for discriminatory behavior are the
attitudes and concerns that clinicians have about PWID.67 In one study of syringe access
programs, although 60.6% of PWID reported seeing a primary care provider within the past year,
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results indicated they were not receiving adequate preventative services or education about harm
reduction.203 Additional work remains to decrease the amount of stigma perceived by opioidmisusing PWID. These findings provide further support for the conclusions of previous studies,
which have called for continued efforts to educate clinicians and the community at large in order
to destigmatize treatment for SUD.
Financial barriers. PSU class was not significantly associated with perceiving a financial
barrier to accessing treatment. In contrast to the previous results, this finding might reflect the
success of current interventions. It was notable that PSU class was not significantly associated
with perceiving a financial barrier to accessing treatment. As this study only included individuals
with insurance, this result could indicate that provisions under the ACA to make coverage of
SUD services equitable to other healthcare services are making SUD treatment more affordable
for insured adults. This supports the results of a previous study, which reported a decrease in
perceived financial barriers to accessing SUD treatment following implementation of the ACA.73
3.4.4 Public health implications
First, understanding the relationship between patterns of PSU and access barriers can be
used to inform public health efforts to address these barriers, and highlight appropriate locations
for resource allocation. Heroin injectors with high PSU were most likely to perceive readiness,
structural, and stigma-related barriers to accessing SUD treatment, therefore interventions to
decrease these barriers should focus on places where Heroin injectors with high PSU are found,
such as needle exchange sites, supervised injection sites, or clinics preventing the spread of
HIV/HCV. In addition to harm reduction sites, efforts to decrease barriers and increase treatment
connection might be provided at emergency departments. Previous literature shows that
individuals with PSU patterns similar to Heroin injectors with high PSU and PPR users with
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high PSU are more likely to be treated in an emergency room as compared to PPR users with low
PSU. In one LCA identifying patterns of substance use among overdose survivors admitted to a
U.S. emergency department between 2017-2018, a significant number of patients fell within the
“mostly heroin overdose” (45%) or “opioid, polysubstance” (11%) classes, while less than a
third (27.3%) fell into the “mostly non-heroin opioid overdose” class.188 Several studies have
reported that interventions initiated in the emergency department (e.g., initiation of medication
assisted treatment, peer support) to connect overdose survivors with treatment can increase the
engagement in SUD treatment or harm reduction services following discharge.204–206
3.4.5 Strengths and limitations
Strengths. This study was the first to characterize patterns of PSU within a nationally
representative population of opioid-misusing adults in the U.S. The NSDUH assures privacy and
confidentiality of answers to increase the likelihood of honest reporting of illicit drug use and
illegal activities, and the response rate for each of the three years included in this study were
high, ranging between 69.7-67.1%.207
As opposed to previous studies where substances were required to have a prevalence of
15-20% to be included as an indicator variable in LCA,132,155,165,166,168,170 this study included past
year use of all licit/near licit, illicit, and prescription misuse reported to the NSDUH. In addition,
in contrast to all other U.S. studies investigating patterns of PSU, this study included information
about tobacco use and smoking.
Limitations. The findings of this study should also be viewed within the context of
several limitations. First, the data are cross-sectional and derive from self-reported substance use
within the past 12 months, which may be limited due to recall bias and/or social desirability bias.
In addition, these patterns of PSU derived from indicators of past year substance use from a
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nationally representative population. Thus, results may not be generalizable to specific cities or
regions within the U.S. where increased availability of certain street drugs (e.g., crack, cocaine,
methamphetamines) or legality of substance use (i.e. marijuana) might alter observed patterns of
PSU.
Second, the LCA did not account for the complex sampling design of the NSDUH, which
may have resulted in biased parameters and underestimated standard errors.208 In addition, the
findings of the current study may not directly compare to those of previous LCA due to variation
in how alcohol use is captured. For example, several studies included indicators of any alcohol
drinking or use,164,170,171 which makes it difficult to distinguish between less harmful occasional
alcohol use and more problematic binge drinking. Additionally, the definitions for “binge
drinking” varied, including “4 or more drinks on a single occasion”155 and “≥5 of more drinks in
one sitting”.168 Only three studies used indicator variables for binge drinking as defined by the
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (five drinks for men and four for
women in one sitting).166,188,209 Future researchers should consider using the NIAAA definition
of binge drinking to ensure comparability between studies, and aid the development of strategies
to prevent opioid overdoses involving alcohol.
Finally, these findings may be limited due to an inability to differentiate between all
modes of drug administration (i.e., snorting, smoking), and the inability to differentiate between
concurrent vs. simultaneous substance use. In addition, this study did not differentiate between
misuse of prescription opioids primarily prescribed for pain (e.g., oxycodone, fentanyl,
morphine, oxymorphone) and opioids prescribed for treatment of OUD (e.g., buprenorphine,
methadone).
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3.5 Conclusions
Participation in treatment is a necessary step towards ending opioid addiction. This study
demonstrated an association between patterns of PSU and perceived barriers to accessing SUD
treatment among opioid-misusing individuals. These findings highlighted a subpopulation of
opioid users at increased odds of experiencing readiness, structural, and stigma-related barriers to
accessing SUD treatment, and provided strong evidence that additional steps are necessary to
decrease barriers to treatment perceived by individuals reporting high PSU. These findings also
underscored the importance of re-evaluating the admissions process for SUD treatment, and
providing further education to clinicians and the community to decrease stigma towards
individuals with SUD. The current study added information to the contributions of previous
literature that could be used to encourage the development of interventions that help opioidmisusing individuals seeking SUD treatment to overcome the barriers that they are most likely to
face. Decreasing perceived barriers to accessing care are necessary in order to increase
enrollment in SUD treatment.
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Chapter 4. Evaluating the impact of an out-of-hospital initiated opioid treatment
connection program on the number of nonfatal opioid overdoses 24-months post
intervention
Background: The steady rise in opioid-related mortality has led to rise in interventions aimed at
connecting opioid-misusing individuals to treatment for substance use disorder (SUD). On
February 1st 2018 the Chesterfield Fire and EMS Community Paramedicine Program
implemented an out-of-hospital intervention aimed at connecting survivors of nonfatal opioid
overdose (OOD) to treatment for SUD. The objective of this study was to evaluate the
association between the implementation of this out-of-hospital intervention and the trend of
monthly nonfatal OOD in the county of implementation.
Methods: We utilized EMS electronic patient care records in Virginia from February 1, 2016 to
January 31, 2020. Incidents where naloxone was administered with patient improvement were
included for Virginians aged 18-89. Two interrupted time series (ITS) analyses were conducted
using Poisson regression to assess changes to the trend of monthly nonfatal OOD from preintervention to post-intervention. Analyses included single ITS of Chesterfield County and
multiple ITS comparing trends in both Chesterfield County and a comparable control county.
Results: Of the 16,719 911 responses to a nonfatal OOD in Virginia during the study period,
1,034 (6.0%) occurred in Chesterfield County and 879 (5.3%) in the control county. Single ITS
showed an immediate decrease in nonfatal OOD by 0.33% each month (p=0.0857), and no
statistically significant difference between the post-intervention trend and the pre-intervention
trend (p=0.9195). There were no statistically significant differences in the pre-intervention level
or trend of monthly nonfatal OOD between counties, indicating comparability. The postintervention level was approximately 0.18% lower for Chesterfield (p=0.5150), and the
difference in the differences of slopes between counties from pre-to-post intervention was 0.02%
(p=0.2404).
Conclusions: These findings provide initial support for the effectiveness of an out-of-hospital
intervention that links survivors of nonfatal OOD to treatment for SUD.
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4.1 Introduction
4.1.1 The Opioid Epidemic in Virginia
In 2017, the opioid epidemic caused the deaths of 1,445 Virginians, an 8% increase in
fatalities from 2016.210 Opioid-related incidents have burdened healthcare and public safety
resources throughout the Commonwealth, resulting an annual average of 10,000 emergency
department visits and 4,000 emergency medical services (EMS) responses211 in 2017, and one
opioid-related criminal arrest every two hours.212 Accumulating costs from the impact of opioid
misuse on public safety and other state services has had a broad impact on the Virginia’s
economy, with one study estimating the per capita cost of the opioid epidemic at $1,624 per
resident, equivalent to nearly 3% of the overall gross domestic product in Virginia.213 Although
the continued needs of the opioid epidemic have pushed the General Assembly of Virginia to
invest a great deal of money between 2017 and 2018214 to fund public health initiatives aimed at
decreasing opioid-related morbidity and mortality, the steady increase in fatalities despite these
efforts highlight the need to address potential gaps that may persist.
4.1.2 VA Initiatives to Decrease Opioid-Related Morbidity
Similar to many states throughout the nation, Virginia has acknowledged the serious
consequences of the opioid epidemic, declaring that “a public health emergency resulting from
opioid addiction exists in the Commonwealth, affecting the health and safety of Virginians” on
November 21st, 2016.215 Virginia officials addressed the public health emergency through
implementation of interventions aimed at preventing future addiction and decreasing overdose
fatalities. To promote the appropriate use of controlled substances, in July of 2017 Virginia
mandated all prescribers to register for the prescription monitoring program (PMP), an online
database which enabled prescribers to monitor their patient’s use of controlled substances, and
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more effectively deter potential misuse and diversion.216 To decrease deaths due to accidental
overdoses, Virginia took steps to increase civilian access to the opioid-antidote naloxone. The
Commonwealth medical director released standing order in 2016 which allowed for the over-thecounter prescription of naloxone,217–219 and in 2017 the opioid overdose and naloxone education
program REVIVE! was initiated, which dispensed naloxone at no cost through community
trainings and local health departments throughout Virginia.220,221 Finally, to decrease the
incidence of Human Immunodeficiency Virus (HIV) and Hepatitis C among injection drug users,
in 2018 the Commonwealth opened two needle exchange programs.222–224
Various key public health initiatives have been implemented successfully throughout the
nation, each recommended by the Centers for Disease Control as a key strategy to decrease
opioid overdose (OOD) morbidity and mortality.225 Despite these efforts, the number of opioidrelated fatalities in Virginia has continued to rise, from 1,284 in 2016 to 1,445 in 2017.210
One explanation for the rise in deaths could be due to the increased presence of fentanyl
in Virginia. As previously mentioned, fentanyl use has significantly increased throughout the
nation since 2013, accounting for 77% of the total increase in deaths attributed to heroin.226 This
trend was also reported in Virginia according to Attorney General Mark Herring, who stated in a
press briefing that “fentanyl has become the biggest driver of the rise in overdose deaths in
Virginia”.227 Deaths due to fentanyl in the Commonwealth have increased by 1,337% since
2009227 and continue to rise, increasing by 23.4% from 2016 to 2017.228
However, the upward trending of opioid-related fatalities could also be attributed to the
policy emphasis on implementing initiatives rooted in primary and tertiary prevention-based
approaches, rather than secondary prevention approaches which would emphasize screening and
treatment. PMP are a primary prevention strategy, allowing surveillance of individuals who use
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prescription opioids to prevent and deter further misuse; whereas both needle exchange and
naloxone distribution programs represent tertiary prevention strategies, reducing either risk of
blood-born pathogen transmission or risk of fatal overdose among individuals already misusing
opioids.229,230 Although multiple studies have demonstrated the effectiveness of these strategies
in decreasing opioid-related morbidity,225,229 these initiatives are ultimately limited in that they
do not directly address treatment for opioid addiction. Virginia Governor Dr. Ralph Northam
highlighted the importance of both treatment and prevention in a 2018 address to medical
students discussing the opioid epidemic, emphasizing that state efforts to address the opioid
crisis must involve both prevention and treatment, stating “…when prevention does fail,
treatment works”.231 However, since this address no additional funds or programs have been
initiated to increase access to treatment, and as 464,000 Virginians reported needing but not
receiving treatment for substance use in 2016, additional initiatives to ensure better access to
treatment were clearly warrented.232
4.1.3 VA Initiatives to Increase Access to Addiction Treatment
One program aimed at increasing access to addiction treatment for Virginians' was the
Addiction Recovery and Treatment Services or ARTS program, implemented in April of 2017.214
ARTS increased the number of available addiction treatment providers by making addiction
treatment more cost effective for practitioner to provide, resulting in increased access to
treatment for Medicaid members with opioid and other substance use disorders.214,233–235
Following ARTS implementation the number of outpatient opioid treatment services in Virginia
increased from 6 to 108,234 and evaluators reported a 51% increase in the treatment rate of
Medicaid members with Opioid Use Disorder (OUD) over the first five months of the
program.233 Though initially restricted due to the limited number of individuals covered by
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Medicaid in a non-expansion state, access through ARTS is expected to further increase in
January of 2019, when the expansion of Medicaid throughout the Commonwealth will increase
Medicaid coverage to an additional 400,000 individuals.236
In addition to expanding access to addiction recovery and treatment services for Medicaid
recipients through ARTS, in May 2018 Governor Ralph Northam accepted a Federal grant of
over 9.7 million dollars for the Department of Behavioral Health and Developmental Services,
expected to help fund the Virginia Community Services Boards, which provide prevention,
treatment, and recovery services to all Virginians.211
4.1.4 Limitations to VA Initiatives
While initiatives to improve access to addiction treatment in Virginia have yielded
promising results, limitations remain. The continued rise of opioid-related fatalities despite
implementation of the ARTS program could be attributed to the restricted number of individuals
eligible for Medicaid who qualify for participation in the program.214 Although increased access
is expected with Medicaid expansion in 2019, the benefits of the program will remain limited
only to individuals covered by Medicaid, likely excluding a significant proportion of the opioid
addicted population who are in need of addiction treatment but are either not qualified for
Medicaid,237 or are eligible but unable to enlist.238 Further, although the 2014 passage of the
Patient Protection and Affordable Care Act (ACA) expanded insurance to many Americans,45
passage of the ACA was not associated with increased use of treatment for substance use
disorder (SUD) among individuals with substance use disorders,21 indicating additional
initiatives to engage these individuals may still be warranted.38 Low treatment enrollment in this
population could persist due to logistical barriers to access (ie. transportation),239 or lack
knowledge on where to access these resources.21 Finally, these interventions will likely have
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little impact on individuals declining to seek treatment due to motivational or stigmatization
barriers, which are more common among the insured population.22
4.1.5 Healthcare Partnerships Connecting Addicts with Treatment
To better address these remaining gaps, additional efforts should focus on connecting
opioid-abusing individuals to treatment and supporting them throughout the treatment process.
Governor Northam highlighted the importance of these programs by allocating additional
funding from his $9.7 million dollar Federal grant to “support the development of partnerships
with the hospital that will connect individuals who overdose with peers in recovery”.211 Although
hospital partnerships connecting individuals with peers during the recovery period have
demonstrated early success,240 limiting inclusion to hospital-based partnerships could potentially
exclude a significant proportion of the opioid-abusing population, as prehospital research reports
63-69% of patients refuse transport to the hospital following an OOD,241,242 or depart prior to
physician discharge against medical advice.243 Further, as studies suggested that individuals with
access to naloxone could be less likely to call for assistance following an overdose,244 the
increased availability of naloxone in the Commonwealth could lead to a decrease in the number
of individuals seeking treatment at a hospital following an overdose. Thus, to expand the effort
of treatment-connection initiatives in the opioid-abusing community, it may be beneficial to
explore not only hospital partnerships, but also partnerships with public safety personnel,
specifically, emergency medical services (EMS).
4.1.6 Feasibility of EMS Personnel Connecting Patients to Addiction Treatment
The recent expansion of EMS personnel into non-emergent healthcare roles further
supports their partnership viability. Although designed to respond to emergency situations, many
EMS agencies now participate in mobile integrated health care or community paramedicine;
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programs which enable EMS personnel to provide individualized patient care in a non-emergent
role.245 Many of these programs were designed to use EMS personnel to help patients navigate
the healthcare system to find and access available resources.246 Individualized to the needs of the
patient, community paramedicine programs provide a variety of services, including: management
of chronic diseases, assessing and addressing hazards in the home, or accessing and arranging
medical appointments.245,246 Research has demonstrated these programs are extremely effective
at connecting patients with healthcare resources, resulting in decreased use of EMS, decreased
visits to the emergency department, decreased hospital readmissions.247,248 Further, participants
of these programs report being highly satisfied with the care they receive from the community
paramedics.246 The success of these programs demonstrate EMS personnel can effectively
connect patients with healthcare resources in the community, providing further support for the
use of EMS personnel in connecting opioid-misusing patients with treatment.
Although few studies have reported the implementation of overdose related intervention
and treatment connection programs by public safety personnel, emerging results from these
studies are promising. A 2017 survey in Massachusetts reported that 21% of public safety
agencies were administering some form of outreach program for opioid addicts.249 Administered
primarily by law enforcement and fire, some interventions reported encouraging results; with one
program of police-led referrals successfully placing 75% of those seeking addiction treatment
services into care.250 However, no study has yet evaluated the effectiveness of programs using
EMS personnel to connect patients with treatment for SUD. The promising results of programs
implemented by other public safety officials further support the feasibility of a program
implemented by EMS personnel.
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4.1.7 Study Aims and Hypothesis
Although various interventions have aimed to increase the availability of addiction
treatment throughout the nation, many individuals in need of addiction treatment remain without.
Programs where health-care providers connect opioid-misusing individuals to addiction
treatment and peers in addiction recovery are currently recommended, but underutilized in the
out-of-hospital environment. While early research has demonstrated that public-safety outreach
programs can be effective in referring individuals to addiction treatment facilities, at the date of
this writing no programs have evaluated the effectiveness of an intervention implemented by
EMS personnel. This is the first evaluation of an out-of-hospital intervention implemented by
EMS personnel to link survivors of OOD with treatment for substance use disorders.
The objective of this study was to evaluate the impact of the Chesterfield Fire & EMS
Community Paramedicine Peer Support and Treatment Connection (PSTC) program on the trend
of monthly nonfatal OODs, 24 months after implementation of the program. We hypothesized
that Chesterfield County would see a significant decrease in the level of monthly nonfatal OODs
immediately after implementation of the PSTC program, and a gradual decrease in the trend of
monthly nonfatal OODs over the 24-month post-intervention period, as compared to the 24month pre-intervention period. Additionally, we hypothesized that pre- to post implementation
differences in the trend of monthly nonfatal OODs would be significantly lower for Chesterfield
County in comparison to an adjacent “control” county.
4.2 Methods
4.2.1 Study Design
This study used a quasi-experimental interrupted time-series design to compare changes
in the trend of monthly nonfatal OODs before and after implementation of the PSTC program.
Observations of nonfatal OODs were collected simultaneously in Chesterfield County and an
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adjacent county over four years and split into two time periods: pre-intervention (February 1st
2016 – January 31st 2018) and post-intervention (February 1st 2018 – January 31st 2020).
4.2.2 Study Intervention
On February 1st 2018 the Chesterfield County Fire and Rescue Community Paramedicine
Program partnered with a peer support specialist for an opioid outreach intervention that aimed
to connect survivors of nonfatal OOD treated by Chesterfield EMS with an addiction treatment
program within Chesterfield County or the surrounding area. Following an EMS response for an
OOD, a Chesterfield Community Paramedic and peer support specialist follow up with the
patient by phone to schedule a meeting. During the meeting, the team encourages the individual
to seek treatment for opioid misuse, and offers to help connect them to local treatment programs
within the county or surrounding area. If the individual agrees, the peer support specialist works
one-on-one to enroll them in treatment programs. The services provided by the community
paramedicine team and the peer support specialist vary, as services are individualized to meet the
needs of each participant. The team may call to follow up with the participant if they need
counseling or may attend the mental health evaluations with the participant at their request. Once
a participant completes a mental health evaluation, they become eligible for the community
health services provided by the Chesterfield County Community Services Board, and their
participation in the program ends.
4.2.3 County Populations and Emergency Medical Services
Chesterfield County is the 4th most populous county in Virginia, with an estimated 2018
population of 348,556. Chesterfield County Fire and Rescue is the largest provider of EMS in
Chesterfield County, and responded to 69.6-81.2% of the nonfatal OODs during the study
period. In addition to Chesterfield Fire and EMS, EMS are provided by four volunteer rescue
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squads, and a large metropolitan service from a neighboring county, which responded to 19.321.0% of nonfatal OOD during the study period.
The control county was chosen due to the similarities in demographic characteristics and
the provision of EMS within the county. Supplemental Table 4.1 summarizes the population
characteristics and OOD characteristics for each county in 2018. Located adjacent to
Chesterfield County, the control county is the 5th most populous county in Virginia, with an
estimated 2018 population of 329,261. Similar to Chesterfield, the control county-run fire
department is the primary provider of EMS, and responded to 65.4-75.3% of nonfatal OODs
during the study period. EMS in the control county is also supplemented by five volunteer rescue
squads, and a large metropolitan service in a neighboring county, which responded to 12.623.4% of nonfatal OOD during the study period. Up to the time of this writing, the county-run
fire department had not yet implemented a program aimed at connecting survivors of nonfatal
OOD with resources for addiction treatment.
4.2.4 Data Source and Study Population
Adults between the ages of 18 and 89 were eligible for inclusion in the study if they were
treated by EMS personnel for a nonfatal OOD in Chesterfield County or the control county
during the study period (February 1st 2016 – January 31st 2020). Incidents meeting criteria that
were the result of a non-911 response (interfacility transport, standby, assist) were excluded from
analysis.
Data was extracted from EMS electronic patient care reports (ePCRs) for all incidents of
nonfatal OODs within both counties occurring between February 1st, 2016 and January 31st 2020.
An ePCR is required to be completed by a Virginia certified paramedic or emergency medical
technician after every EMS incident in the Commonwealth of Virginia, then submitted to the
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Virginia Pre-Hospital Information Bridge program located within the Virginia Department of
Health Office of Emergency Medical Services, Division of Trauma and Critical Care.251 All
protected health information was removed using de-identification methods recommended by the
U.S. Health and Human Services.252
Annual estimates for county population were obtained from the Centers for Disease
Control and Prevention Wide-ranging Online Data for Epidemiologic Research.
4.2.5 Measures
The primary dependent variable of the study was the monthly count of nonfatal OOD for
Chesterfield County and the control county between February 1st, 2016 and January 31st 2020.
A nonfatal OOD was defined as any EMS incident where an individual was administered
naloxone and their condition “improved”.
The primary independent variable was the study period: the period of February 1st 2016 –
January 31st 2018 (pre-intervention period) vs. the period of February 1st 2018 – January 31st
2020 (post-intervention period).
Demographic and incident-related measures were extracted to assess differences in
demographic and incident-related characteristics between the two counties. These included: sex
(male or female), age in years (18-24, 25-34, 35-44, 45-54, 55-64 or ≥65), and race (NonHispanic White, Non-Hispanic Black, or other (Hispanic, Asian, American Indian or Alaska
native, native Hawaiian or other Pacific Islander, “other race”, or selections of multiple races)).
Incident-related characteristics included year of overdose, location of incident (private residence,
residential facility, or public location), route of naloxone administration (intranasal (IN),
intravenous (IV), other (intramuscular, intraosseous, oral, endotracheal tube, topical,
other/miscellaneous), or combined (receiving naloxone through a combination of IN, IM, IV or
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other routes)) and the dose of naloxone administered in milligrams (mg) (0.4-0.9 mg, 1.0-1.9 mg,
2.0-2.9 mg, 3.0-4.9 mg, or ≥ 5.0 mg)).
4.2.6 Analytic Strategy
All statistical analyses were performed using R Studio v3.6.3. Descriptive statistics were
calculated to assess differences in the distribution of demographic and incident-related
characteristics between the two counties, using T-tests for continuous variables and Pearson Chisquare tests for categorical variables.
Interrupted time-series analysis using a Poisson regression model was used to assess the
changes in the level and trend of monthly nonfatal OOD before and after implementation of the
PSTC program. Development of the model and analysis were based on an interrupted time series
regression tutorial developed by Bernel et. al.253
This times series analysis was performed using two models: a single interrupted time
series (SITSA) model which assessed changes in the pre- and post-intervention trend of monthly
nonfatal OOD before and after intervention implementation in Chesterfield, and a multiple
interrupted time series (MITSA) model, which assessed changes in the pre- and post-intervention
trends of monthly nonfatal OOD between Chesterfield County and the control county.
The equation for SITSA is based on segmented linear regression:254
yT = β0 + β1T + β2X + β3XT + ε
In this model, yT is the average of nonfatal OODs at month T, T is the continuous time (in
months) from the start of the pre-intervention period on February 1st 2016 to the end of the
implementation period on January 31st 2020. X is a binary variable that indicates intervention
implementation (0=pre-intervention, 1=intervention), and XT is an interaction term that
represents time after intervention implementation. β0 is an estimate of the baseline count of
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monthly nonfatal OODs, β1 estimates the average change in monthly nonfatal OOD during the
pre-intervention period, β2 estimates the level change in monthly nonfatal OOD immediately
after intervention implementation, β3 estimates the average change in monthly nonfatal OOD
from pre- to post-intervention, and ε is an error term that represents random variability that was
not accounted for in the model. In addition, β1+3 was calculated to show change in the average
monthly nonfatal OOD during the post-intervention period.
The equation for the MITSA model is an expansion of the SITSA equation that adds in a
control series. This control series was used to assess whether the level and slope changes
observed in the treatment county (Chesterfield) are significantly different from those observed in
the control county.254
yT = α + β1T + β2X + β3XT + β4Z + β5ZT + β6ZX + β7ZXT + ε
In this equation, Z is a binary variable that codes treatment status (1=treatment, 0=control), and
ZT, ZX, and ZXT are all interaction terms among the aforementioned variables.255 In this model
the purpose of coefficients β0 – β3 are the same as those described in the SITSA model, but now
provide estimates for the control county. β4 estimates the pre-intervention difference in the level
of the outcome between treatment and control, β5 estimates the pre-intervention difference in the
slope of the outcome between treatment and control, β6 indicates the difference between
treatment and control in the level immediately following introduction of the intervention, and β7
indicates the difference between treatment and control groups in the trend of the outcome
variable after initiation of the intervention compared to the pre-intervention trend.255
Results of the observed and predicted trends for each model were plotted to visually
demonstrate the curve-shifting. The Pearson-based dispersion statistic was used to assess for
overdispersion in each model.256 If overdispersion was found, models were adjusted in a
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quasipoisson model, which allows variance in the model to be proportional rather than be equal
to the mean. In addition, autocorrelation, or the correlation of a variable with itself at different
time periods, was assessed in both the SITSA and MITSA models through visual inspection of
the sample autocorrelation and residual plots, and use of the Breusch-Godfrey test statistic.
4.2.7 Statement of Ethics
This study utilized de-identified data; no variables in the assessment could be used to
identify patients, or indicate status of vulnerable patient populations (i.e., pregnant women or
prisoners). This study was therefore approved as exempt from review by the Institutional Review
Board at Virginia Commonwealth University, ID= HM20016514.
4.3 Results
Of the 16,719 911 responses to a nonfatal OOD during the study period, 1,034 (6.0%)
occurred in Chesterfield County and 879 (5.3%) in the control county. Table 4.1 describes the
demographic and incident-related characteristics for nonfatal OODs by county. In comparison to
nonfatal OOD responses in the control County, Chesterfield County reported a higher prevalence
of female patients (38.9% vs. 33.1%), a lower prevalence of Non-Hispanic Black patients (22.5%
vs. 32.1%), and reported more overdoses occurring in a private residence (67.9% vs. 59.5%).
Further, in contrast to patients in the control county, patients in Chesterfield were predominately
administered naloxone intra-nasally (60.4% vs. 28.2%). Additionally, the average total dose of
naloxone administered to patients was significantly higher in Chesterfield (3.2 mg vs. 1.8 mg),
and over half (54.2%) of Chesterfield patients received a dose of 3.0mg or higher, compared to
15.5% of patients in the control county.
The dispersion statistic for the SITSA quasipoisson model was 2.18, indicating that the
conditional variance was at least two times larger than the conditional mean. Adjusted
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estimates showing trends in observed and predicted monthly nonfatal OOD in Chesterfield
County are included in Table 4.2, and are further illustrated in Figure 4.1. Pre-adjustment
estimates were included in Supplemental Table 4.2. The pre-intervention trend (β1) in
Chesterfield County showed an increase in monthly nonfatal OODs by about 0.01% each
month. There was an immediate decrease in monthly nonfatal OOD by 0.33% following
implementation of the intervention, however this estimate was not statistically significant
(p=0.0857). Additionally, there was no statistically significant difference between the postintervention trend and the pre-intervention trend (p=0.9195), and the estimated postintervention trend (β1+3) appeared very similar to the pre-intervention trend, showing an
increase in monthly nonfatal OOD by 0.02%. On visual inspection the residuals appear to be
randomly distributed, showing no patterns (Supplemental Figure 4.1), further the correlogram
for autocorrelation revealed no lags in time where autocorrelation was statistically significant
(Supplemental Figure 4.2).
The dispersion statistic for the MITSA quasipoisson model was 2.02, indicating that
the conditional variance was approximately two times larger than the conditional mean.
Adjusted estimates of the MITSA are reported in Table 4.3, and predicted pre- and postintervention trends for both counties are presented in Figure 4.2. Unadjusted estimates are
available for comparisson in Supplemental Table 4.3.
Table 4.3 reports the results of the MITSA between Chesterfield and the control county.
Monthly averages of nonfatal OOD for both counties are plotted in Figure 4.2. In contrast to
Chesterfield, the pre-intervention trend (β1) in the control county showed a decrease in monthly
nonfatal OOD by .003% each month (p=0.7512). Immediately following initiation of the
intervention, monthly nonfatal OOD decreased by 0.15% (p=0.4702). There was no statistically
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significant difference between the pre-intervention trend and the post-intervention trend (β3),
showing an approximate 0.02% increase in the monthly average nonfatal OODs (p=0.0953).
Chesterfield and the control county did not show any statistically significant differences in the
pre-intervention level (β4) or trend (β5) of monthly nonfatal OOD, indicating that the two series
were comparable prior to intervention implementation. There were no statistically significant
differences in the pre- to post-intervention differences in level (β6) or trend (β7) between
Chesterfield and the control county. The post-intervention level was approximately 0.18% lower
for Chesterfield compared to the control county (p=0.5150), and the difference in the differences
of slopes between counties from pre-to-post intervention was 0.02% (p=0.2404).
Residuals from the MITSA appeared to be randomly distributed with no clustering or
patterns (Supplemental Figure 4.3), and visual inspection for autocorrelation revealed no lags in
time where autocorrelation was statistically significant (Supplemental Figure 4.4).
4.4 Discussion
The SITSA found no statistically significant pre- to post-intervention differences in the
average monthly number of nonfatal OODs in Chesterfield County. An immediate reduction was
observed in the average monthly nonfatal OOD following program implementation, however this
difference was not statistically significant. Additionally, there was no significant difference in
the trend of average monthly nonfatal OOD from pre- to post-intervention. In the MITSA, there
was a difference observed in the pre- to post-intervention trends for the control county. The postintervention trend showed a minimal increase in monthly nonfatal OOD compared to the trend of
nonfatal OOD pre-intervention, however this difference was not statistically significant. There
were no statistically significant differences for both the pre-intervention trend and the preintervention level between Chesterfield and the control county. Chesterfield saw a greater

71

reduction in monthly nonfatal OODs immediately following program implementation compared
to the control county, however this difference was not statistically significant. In addition, there
was no statistically significant difference in the differences between the pre- to post-intervention
trends for each county.
4.4.1 Results of MITSA model
The trend of monthly average nonfatal OODs in Chesterfield County did not significantly
change from pre-intervention to post-intervention. A lack of significant change between the preintervention and post-intervention trends usually indicate that the intervention under
investigation may not be sustainable over time. However, the MITSA showed the trend of
nonfatal OODs in the control county significantly increased from pre-intervention to postintervention. The key assumption when using MITSA is that change in the level or trend in the
outcome would be similar for the control and for the treatment group, had the intervention not
been implemented255. This suggests that implementation of the intervention may have delayed or
slowed a rise in the trend of nonfatal OODs in Chesterfield County that would have been
expected if the intervention had not been implemented.
4.4.2 Unmeasured potential confounders impacting analysis
Overall, the differences between the two counties for the estimates of pre- to postintervention change for the level and trend of nonfatal OODs were not statistically significant.
This could be due to the co-occurring implementation of other opioid-related interventions,
which may impact one county more than the other. The key assumption behind comparison with
a control county, is that confounding omitted variables would affect the treatment and control
groups similarly.255 Yet it is possible that some of the co-occurring opioid-related interventions
had a differential impact on the counties.
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The disproportionate prevalence of fentanyl between the counties could impact the
monthly average of nonfatal OODs. In Virginia, fentanyl-related mortality spiked at the
beginning of the study period, increasing by 177.3% from 2015 to 2016.228 Data from the Office
of the Virginia Medical Examiner show that the 2016-2018 fentanyl-related mortality rate per
100,000 was 8.0 to 13.8 in Chesterfield, compared to 6.4 to 11.2 in the control county.257 Ideally,
fentanyl would be accounted for through stratification,258 which would allow for evaluation of
the differential impact of the intervention on subpopulations of nonfatal OODs with and without
fentanyl. Unfortunately, EMS ePCRs lack a standardized way of reporting fentanyl involvement
during a nonfatal OOD. Even if documented, the accuracy of self-reported data would still be
questionable, as many individuals may not know the heroin they purchased had been cut with
fentanyl.259 Further research is needed to determine whether this intervention would have a
differential impact on the monthly average nonfatal OODs after controlling for fentanyl.
Legislation increasing the availability of naloxone in Virginia, such as naloxone
distribution programs and over-the-counter availability of naloxone, may also impact the
counties differently.260 Prevalence of bystander naloxone may impact the monthly average of
nonfatal OOD, as individuals administering naloxone may be less willing to call 911, either out
of fear for police involvement,261,262 or because they feel they can handle the overdose
themselves.263,264 Thus, prevalence of bystander naloxone may increase the likelihood of an
individual overdosing without summoning 911, which would underestimate the true count of
nonfatal OODs in the community. Accounting for the presence of bystander naloxone in Virginia
would be challenging. To the author’s knowledge, the REVIVE! program does not keep a record
of the number of residents receiving naloxone training, or the number of naloxone units
distributed in each county. However, prior naloxone administrations, or naloxone administered
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prior to the arrival of EMS personnel, could be used as a proxy to account for the presence of
bystander naloxone within the community. A previous analysis of 2016-2018 nonfatal OODs in
both counties revealed that Chesterfield had a disproportionately high number of prior naloxone
administrations compared to the control county. Thus, it is possible that individuals in
Chesterfield could be less likely than those in the control county to summon 911 to the scene of
an overdose. This would result in the underestimation of the true count of OOD each month, and
have a differential impact on the monthly average of nonfatal OODs in the two counties.
4.4.3 Strengths
This study has several strengths. Interrupted time series allows researchers to perform a
robust analysis of a dependent variable without incurring the cost and work associated with a
randomized control trial.258 The interrupted time series approach enables us to evaluate the effect
of the Chesterfield intervention program on the monthly average of nonfatal OODs in
Chesterfield County, while accounting for the pre-implement trend for the monthly average of
nonfatal OODs.
An additional strength of this study is the inclusion of a non-equilivant control group in
our MITSA, which enhances the internal validity of the analysis by allowing the researcher to
control for omitted confounding variables.253,255
4.4.4 Limitations
However, the results of this study should also be viewed in the context of several
limitations. The data used for this study were de-identified and unlinked, meaning it is possible
that an individual could have been treated multiple times during the study period. However, it is
unlikely that the occurrence of a “repeat overdose” would differ between counties. In addition,
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the analysis was limited to records from two counties in the Commonwealth of Virginia, which
may limit the generalizability of these results to other jurisdictions.
In addition, on January 1st, 2017 the Virginia Office of EMS stopped accepting ePCRs
from EMS agencies not using data submission standards for National Emergency Medical
Services Information System version 3.4. This initially resulted in the exclusion of all incidents
from Chesterfield Fire and EMS, and all volunteer rescue squads in Chesterfield County for
January and February of 2017. While Chesterfield Fire and EMS was able to provide researchers
with the cumulative number of eligible cases for those two months, data from volunteer rescue
squad responses were not available; which may have slightly underestimated the true count of
nonfatal OODs in Chesterfield County for those two dates.
Further, previous researchers have questioned the accuracy of using EMS naloxone
administrations as a proxy for nonfatal OODs, reporting low sensitivity and positive predictive
value for the use of naloxone administrations alone.265 While our definition (i.e., EMS patients
who received naloxone and improved) increased precision by excluding false-positive cases (i.e.,
OOD patients who received naloxone with no improvement), it likely still underestimates the
true number of nonfatal overdoses during the study period, by excluding any individual with an
OOD who was not administered naloxone. This definition also would have excluded individuals
who had an OOD but did not improve until additional naloxone was administered at the hospital,
or individuals who did not improve due to comorbidities secondary to an OOD or
pharmacokinetic effects of a secondary drug unaffected by naloxone administration.
Finally, the accuracy of these findings are dependent upon the accuracy of the ePCRs
created by EMS professionals documenting these incidents.
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4.5 Conclusions
Implementation of an opioid treatment connection program did not appear to have a
statistically significant impact on the monthly average of nonfatal OODs. Although the monthly
average of nonfatal OODs was reduced following program implementation, this association was
not statistically significant. Increasing the number of months for post-intervention analysis may
be needed to more accurately determine whether this intervention has a sustained effect on the
average number of nonfatal OODs each month. Further research is needed to evaluate the
effectiveness of public health interventions implemented by EMS personnel as a part of the
public health strategy to address the opioid crisis.
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Chapter 5: Conclusions
Increasing the enrollment of opioid-misusing individuals into treatment for substance use
disorder (SUD) is necessary in order to achieve sustainable long-term decreases in opioid-related
morbidity and mortality. For this reason, addressing barriers to accessing treatment for SUD is
critically important to increase treatment enrollment. The goal of this dissertation was to produce
results that would provide insight into the persisting barriers to accessing SUD treatment in
opioid-misusing individuals by: testing the association between type of opioid misuse and
perceived readiness, financial, structural, and stigma-related barriers in insured adults reporting
past year opioid misuse (Chapter 2); identifying classes of past year polysubstance use among
opioid-misusing adults in the U.S. and assessing the association between polysubstance use
classes and perceived barriers to accessing treatment for SUD (Chapter 3); and evaluating the
effectiveness of an out-of-hospital opioid treatment connection program on the number of
nonfatal opioid overdoses 24-months post intervention (Chapter 4).
5.1 Type of opioid misuse and perceived barriers to accessing treatment
Chapter 2 provided insight into the degree to which those reporting opioid misuse and
perceived a need for treatment perceived a barrier to accessing treatment. Results from Chapter 2
indicated that 3.7% of insured Americans reporting past-year opioid misuse perceived at least
one barrier to accessing treatment for SUD. Further, individuals with combined heroin and
prescription pain reliever (PPR) misuse were nearly 3 times more likely to perceive readiness
and structural barriers, and nearly 4 times more likely to perceive stigma-related barriers to
accessing treatment for SUD in comparison to individuals who only reported past year misuse of
PPR.
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Results from Chapter 2 could help inform the strategic placement of public-health
interventions aimed at connecting opioid-misusing individuals to treatment for SUD. For
example, interventions could be implemented in areas with a traditionally high prevalence of
heroin injectors or individuals with high polysubstance use (PSU), such as clean needle syringe
services, supervised injection sites, homeless shelters, halfway houses, and the emergency
department. In addition, these findings should serve to further support guidelines for the routine
screening of substance misuse currently recommended by the American Society of Addiction
Medicine5. Individuals with high PSU and people who inject drugs are at greater risk for
psychiatric and medical comorbidities, and often seek emergency or acute care to treat those
conditions.266 Thus, increasing identification of SUD through routine screening during treatment
for psychiatric and medical comorbidities may increase access to treatment for SUD in these
populations.
5.2 Type of opioid misuse and perceived barriers to accessing treatment
In Chapter 3, latent class analysis (LCA) identified three distinct classes of PSU within a
nationally representative sample of individuals reporting opioid misuse in the past year: (1)
Heroin injectors with high PSU, (2) PPR users with low PSU and (3) PPR users with high PSU.
Compared to PPR users with low PSU, Heroin injectors with high PSU and PPR users with high
PSU had 3 times the odds of perceiving readiness barriers, and Heroin injectors with high PSU
were also nearly 2.5 times more likely to perceive structural barriers and 3 times more likely to
perceive stigma-related barriers. No subpopulations in this opioid-misusing population had a
statistically significant association with financial barriers.
Taken together, the results of Chapter 3 further demonstrate how accounting for patterns
of PSU during the assessment of treatment outcomes is crucial for the design and implementation
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of interventions addressing barriers to accessing treatment. For example, in Chapter 2,
individuals with H+PPR were more likely to perceive barriers to treatment compared to
individuals with PPR. However, in Chapter 3 classifying individuals into groups based on their
past year substance use enabled the identification of two distinct subgroups of individuals with
H+PPR that were more likely to perceive barriers to accessing treatment (PPR users with high
PSU, Heroin injectors with PSU). The unique sociodemographic characteristics and substance
use profiles of these two subgroups could be used to more efficiently target interventions aimed
at connecting individuals to treatment. For example, an intervention addressing readiness barriers
may increase opportunities for individuals in both subgroups to interact with social workers or
peer recovery specialists, who could provide counseling or motivational interviewing and discuss
resources for treatment. Although some locations, such as the emergency department, might
offer access to both populations, this intervention could better target Heroin injectors with high
PSU through additional implementation at harm reduction services (e.g., clean needle exchange
sites, supervised injection facilities).
Results of the LCA also identified a class of PSU that might be difficult to connect to
treatment, further supporting the recommendation for physicians to increase routine screening of
SUD. PSU users with high PSU might be more difficult to access for two reasons: 1) PPR users
with high PSU would not be expected to participate in the same harm reduction initiatives as
Heroin injectors with high PSU (e.g., clean needle exchange sites, supervised injection
facilities), and 2) the high prevalence of older adults and lack of any physical signs of addiction
may make this group ‘less identifiable’ as individuals with a SUD. Thus, increasing routine
screening for substance misuse at emergency and acute care facilities could increase the
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identification of this hard-to-reach group that accounted for nearly a quarter of the population,
and enable clinicians to link those individuals to needed resources.
5.3 Type of opioid misuse and perceived barriers to accessing treatment
Chapter 4 discusses an out-of-hospital intervention implemented by emergency medical
services (EMS) personnel and a peer support specialist that connects survivors of nonfatal opioid
overdoses (OOD) to treatment for SUD. Initial findings of this study demonstrated that, on
average, the County of implementation (Chesterfield) showed an immediate decrease in the
monthly number of nonfatal OOD compared to a control county where the intervention was not
implemented. In addition, the difference in the differences in pre- to post-intervention trend
showed that the control county had a slight increase in the post-intervention trend of monthly
opioid overdoses. However, Chesterfield County saw no difference in the trend between pre- and
post-intervention. Thus, although this small sample yielded small effect sizes and no statistical
significance, these findings suggest that in the absence of the intervention, Chesterfield County
may have also experienced an increase in monthly nonfatal OODs. Therefore, these results
provide preliminary evidence that encourages the use of out-of-hospital opioid treatment
connection programs to prevent further increases in the trend of monthly nonfatal OODs.
Many of the services offered by Chesterfield County and other EMS-implemented
programs directly address the barriers identified in the current study. Similar to Chesterfield
County, community paramedics in a Houston program conduct home visits with a peer recovery
coach, who uses motivational interviewing to address readiness barriers in survivors of nonfatal
OOD268. Peer support and recovery specialists could also be used to help patients overcome
stigma-related barriers, as they can offer counseling and support through the treatment initiation
process based on their own lived experiences.
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Out-of-hospital programs can also address financial and structural barriers by connecting
opioid-misusing individuals to available treatment programs most appropriate for their care. In
Chesterfield, a community paramedic is responsible for determining treatment availability and
ensuring program participants are placed in treatment appropriate for their care. This is also
similar to previous programs; in Houston, community paramedics are also responsible for
following up with patients and scheduling all clinical visits.268
In addition, collaborations formed between out-of-hospital programs and treatment
facilities may further decrease barriers to treatment access by enabling program patients to gain
immediate access to treatment. For example, Chesterfield program participants initially had a 10day waiting period to receive a mental health evaluation necessary for entering treatment.
However, six months after program implementation, participants no longer had to wait to receive
this evaluation. Other EMS programs prevent structural delays to accessing treatment by taking it
upon themselves to initiate the initial treatment. In Houston, patients enrolled in the program
following an outreach visit are assessed by a nurse practitioner and provided with a one or twoweek prescription for suboxone as interim treatment until the patient can be connected to a longterm program268. In New Jersey, paramedics can request permission from medical oversight
physicians to provide buprenorphine to eligible patients immediately following an overdose269.
To date, many of the out-of-hospital programs currently available to address barriers to
accessing treatment for SUD are still in the pilot stages, and at the time of this project, none have
assessed the effects of program participation on treatment or population-level outcomes. In this
respect, the final aim of this project is unique as it offers findings for the association between
implementation of an out-of-hospital intervention and a population level outcome (nonfatal
opioid overdoses). Other programs have reported difficulty evaluating the effects of their
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program on treatment outcomes due to small sample sizes269 or difficulty obtaining data due to
data-sharing agreements and/or privacy concerns.268 Future researchers should continue to
evaluate the effects of out-of-hospital programs on treatment outcomes.
5.4 Conclusions
Although barriers to accessing treatment for SUD continue to persist following
implementation of the ACA, the development and implementation of public-health interventions
can be targeted towards the subpopulations most likely to perceive barriers. The findings of this
project identify these subpopulations, and also report encouraging initial findings for an out-ofhospital intervention that might be used to address these barriers. Future research should expand
upon the findings of this project through continued evaluation of innovative intervention
programs that can be used to help opioid-misusing individuals overcome persisting obstacles and
obtain life-saving treatment.
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APPENDIX A: Tables and Figures
Table 1.1: Public Health Initiatives Addressing the Opioid Epidemic in the United States
Initiative
Aim
Effectiveness
PRIMARY PREVENTION
Allow physicians and pharmacists access to a
Studies have suggested that PMP are associated with
patient’s history of controlled substance
Prescription Drug Monitoring
significant declines in visits to multiple providers47, and
prescriptions to prevent aberrant drug-seeking by
Programs
correlated with declines in overall opioid prescribing in states
the patient (visits to multiple providers) or
requiring PMP utilization48
aberrant prescribing practices by doctors7
Limit the number of opioid pills written in an
No studies were found which evaluate effectiveness of state
initial prescription to decrease the risk of
prescription limits, but studies of hospital-based prescriber
Prescription Limits
diversion and physical dependence and reduce the limits have been associated with modest reductions in
overall volume of prescriptions7
mortality270
Allow easy disposal of leftover medications to
Take-back programs only gather a small fraction of existing
Prescription Drug Take-Back
reduce availability of unused controlled
opioids, and are not likely have a minimal impact on reducing
Programs
medications at risk for diversion or misuse49
unused prescription opioids within a community49
TERTIARY PREVENTION
Overdose education programs are effective in improving
Distribute naloxone to community laypersons and
Overdose Education and
knowledge related to recognizing and responding to an
individuals at high risk of opioid overdose to
Naloxone Distribution Programs
overdose, and bystanders and individuals who use opioids can
50
prevent overdose deaths
administer naloxone to reverse an opioid overdose51,52
Pharmacies in states with standing orders stock naloxone and
Increase availability of naloxone to opioid-users
Over-the-counter availability of
dispense it without a prescription54, and adoption of naloxone
and laypersons to increase access in the event of
Naloxone
access
laws has been associated with significant reduction in
an opioid overdose7
opioid-related deaths55
Good Samaritan laws decrease the proportion of opioid-related
deaths, but not significantly55, Good Samaritan laws were also
Enable bystanders to an opioid overdose to call
Good Samaritan Laws
7
not associated with an increase in the use of prescription
911 without fear of being arrested
opioids55
Evidence suggests that access to syringe exchange programs
decreases the risk of disease transmission7, though some
Limit the spread of blood borne infections by
Syringe-Needle Access Programs
7
providing injection drug users with clean needles studies report less effectiveness at preventing Hepatitis C
infection46
Enable use of pre-obtained drugs in hygienic
Overdoses were rare (one per 1,287 injections), but were
Supervised Drug Consumption
settings where trained staff are able to respond to successfully reversed by program staff. Participants in the
Venues
overdoses, decreasing risk of fatal overdose56
program also reported more hygienic disposal of syringes57

Implementation
All 50 states have PMP
• 23 mandate clinician
enrollment
• 13 require use prior to
writing a prescription7
25 states have enacted
prescription limits7
At least 40 states publicize
locations for collection
boxes7
There are NDPs in 15 states
and DC46, or 8% of U.S.
counties53
49 states allow OTC
prescription of naloxone7†

39 states have enacted GSLs7

41 states have syringe access
programs7
None‡

Abbreviations: GSL=Good Samaritan laws, NDP=naloxone distribution programs, OTC=over the counter, PMP=prescription monitoring programs
†
Nebraska is the only state that does not allow over-the-counter prescription of naloxone
‡
Supervised drug consumption venues are currently not legal in the US, evaluation of the program mentioned was performed at an un-sanctioned site in the US57
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Table 2.1: Characteristics of insured U.S. adults by type of opioid misuse (NSDUH 2015-2017)
(N=6,095)

Age
18-25 years
26-34 years
35-49 years
50-64 years
Sex
Male
Female
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Sexual identity
Heterosexual
Lesbian, gay or bisexual
Education level
HS graduate or less
Some college-graduate
Total family income
< $20,000
> $20,000-$49,000
Urbanicity
Large metro
Small metro
Non-metro
Insurance type
Private insurance
Medicaid
Otherb
Survey year
2015
2016
2017
Self-reported health
Fair/poor
Excellent/very good
Severe psychological distressc
No < 13
Yes ≥ 13
Past year IDU
No
Yes
Additional SUD
None
1 additional SUD
2 additional SUD
3 or more SUD

TOTAL
(N=6,095)
N (%w)

HO
(N=127)
N (%w)

PPR
(N=5,580)
N (%w)

H+PPR
(N=388)
N (%w)

2783 (26.0)
1451 (24.1)
1386 (27.9)
475 (22.1)

43 (15.0)‡
42 (33.0)‡
23 (20.5)‡
19 (31.5)‡

2566 (26.1)‡
1286 (23.2)‡
1288 (28.3)‡
440 (22.4)‡

174 (29.1)‡
123 (35.0)‡
75 (23.3)‡
16 (12.7)‡

3067 (53.4)
3028 (46.6)

77 (67.4)†
50 (32.6)†

2762 (52.4)†
2818 (47.6)†

228 (64.5)†
160 (35.5)†

3979 (69.6)
664 (10.2)
572 (6.3)
880 (13.9)

90 (72.2)
13 (14.8)
10 (4.0)
14 (9.2)

3587 (69.2)
635 (10.1)
535 (6.5)
823 (14.1)

302 (75.9)
16 (8.8)
27 (4.2)
43 (11.2)

5188 (89.4)
841 (10.6)

110 (90.8)
15 (9.2)

4760 (89.6)
764 (10.4)

318 (86.7)
62 (13.3)

2544 (37.4)
3551 (62.6)

79 (55.8)‡
48 (44.2)‡

2252 (36.2)‡
3328 (63.8)‡

213 (48.9)‡
175 (51.1)‡

1590 (21.6)
4505 (78.4)

65 (56.4)‡
62 (43.6)‡

1390 (20.0)‡
4190 (80.0)‡

135 (33.6)‡
253 (66.4)‡

2707 (56.9)
2224 (30.7)
1164 (12.4)

62 (64.0)
43 (27.5)
22 (8.5)

2481 (56.7)
2026 (30.7)
1073 (12.6)

164 (56.7)
155 (32.8)
69 (10.5)

3704 (64.0)
1882 (27.3)
509 (8.7)

41 (33.7)‡
74 (58.3)‡
12 (8.0)‡

3527 (66.6)‡
1588 (24.8)‡
465 (8.7)‡

136 (35.0)‡
220 (55.7)‡
32 (9.5)‡

2190 (34.5)
1988 (34.3)
1917 (31.3)

33 (24.2)
53 (37.6)
41 (38.2)

2029 (34.8)
1795 (34.0)
1756 (31.2)

128 (32.4)
140 (37.4)
120 (30.2)

2971 (49.8)
3123 (50.2)

87 (71.9)‡
40 (28.1)‡

2664 (48.9)‡
2915 (51.1)‡

220 (56.1)‡
168 (44.0)‡

3877 (68.3)
2218 (31.7)

72 (57.5)‡
55 (42.5)‡

3622 (69.6)‡
1958 (30.4)‡

183 (50.9)‡
205 (49.1)‡

5366 (87.7)
729 (12.3)

50 (38.6)‡
77 (61.4)‡

5195 (92.4)‡
385 (7.6)‡

121 (29.8)‡
267 (70.2)‡

3863 (67.7)
1573 (23.3)
449 (6.4)
197 (2.6)

83 (69.2)‡
24 (17.7)‡
15 (10.4)‡
5 (2.7)‡

3606 (69.0)‡
1433 (22.9) ‡
373 (6.0)‡
158 (2.1)‡

174 (45.5)‡
116 (32.5)‡
61 (11.4)‡
34 (10.6)‡

%w=weighted percent, H+PPR=heroin and prescription pain reliever use, HS=high school, H=heroin use only, IDU=injection drug use, N=sample size,
NSDUH=National Survey on Drug Use and Health, PPR=prescription pain relievers use, SUD=substance use disorder.
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001
a
Comprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race
b
Comprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”
c
K6 scale measures symptoms of psychological distress during the past 30 days, a score ≥ 13 indicates severe psychological distress within the past year
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Figure 2.1: Perceived barriers by type of opioid misuse among respondents who reported at least one
perceived barrier to accessing substance use disorder treatment (NSDUH 2015-2017) (N=244)
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Table 2.2: Adjusted odds ratios for perceived barriers to accessing substance use disorder treatment in
the past year by insured adults with past year opioid misuse (NSDUH 2015-2017) (N=6,029)

Age
18-25 years
26-34 years
35-49 years
50-64 years
Sex
Male
Female
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Othera
Sexual identity
Heterosexual
Lesbian, gay, or bisexual
Education level
HS graduate or less
Some college-graduate
Total family income
< $20,000
> $20,000
Urbanicity
Large metro
Small metro
Non-metro
Insurance type
Private insurance
Medicaid
Otherb
Survey year
2015
2016
2017
Self-reported health
Excellent/very good
Fair/poor
Severe psychological distressc
No < 13
Yes ≥ 13
Past year IDU
No
Yes
Additional SUD
Type of opioid misuse
PPR
HO
H+PPR

Readiness Barrier

Financial Barrier

Structural Barrier

aORa (95% CI)

aORa (95% CI)

aORa (95% CI)

Stigma-Related
Barrier
aORa (95% CI)

Referent
1.19 (0.58-2.42)
1.12 (0.59-2.12)
0.52 (0.20-1.36)

Referent
1.85 (0.81-4.24)
1.28 (0.61-2.69)
0.25 (0.03-2.52)

Referent
1.89 (1.07-3.33)*
1.14 (0.58-2.21)
0.73 (0.22-2.43)

Referent
1.03 (0.52-2.06)
0.90 (0.35-2.31)
0.58 (0.12-2.76)

0.81 (0.43-1.51)
Referent

0.88 (0.49-1.57)
Referent

0.77 (0.40-1.52)
Referent

0.78 (0.42-1.44)
Referent

Referent
0.43 (0.18-1.05)
1.10 (0.49-2.48)
1.12 (0.57-2.19)

Referent
0.69 (0.18-2.69)
1.22 (0.34-4.32)
0.17 (0.05-0.54)†

Referent
0.82 (0.35-1.94)
1.98 (0.85-4.58)
1.14 (0.47-2.76)

Referent
0.46 (0.08-2.71)
1.84 (0.60-5.62)
0.70 (0.26-1.88)

Referent
1.70 (1.00-2.90)*

Referent
1.17 (0.54-2.50)

Referent
1.52 (0.79-2.92)

Referent
1.36 (0.64-2.88)

Referent
1.40 (0.83-2.37)

Referent
0.78 (0.36-1.67)

Referent
0.87 (0.48-1.57)

Referent
1.37 (0.58-3.27)

1.31 (0.73-2.33)
Referent

1.85 (0.79-4.33)
Referent

1.16 (0.60-2.23)
Referent

2.82 (1.43-5.56)†
Referent

Referent
0.78 (0.43-1.41)
0.91 (0.47-1.75)

Referent
0.95 (0.50-1.77)
1.17 (0.52-2.65)

Referent
0.94 (0.57-1.57)
1.33 (0.66-2.65)

Referent
1.88 (0.97-3.65)
1.77 (0.63-4.93)

Referent
1.54 (0.88-2.70)
3.12 (1.43-6.81)†

Referent
2.32 (0.88-6.16)
1.25 (0.52-3.01)

Referent
1.66 (0.66-4.15)
2.03 (1.05-3.94)*

Referent
1.06 (0.36-3.13)
0.50 (0.19-1.27)

Referent
0.78 (0.41-1.49)
1.22 (0.65-2.28)

Referent
0.75 (0.37-1.52)
1.02 (0.52-2.01)

Referent
1.16 (0.60-2.26)
0.80 (0.44-1.46)

Referent
0.64 (0.24-1.75)
0.98 (0.52-1.84)

Referent
1.25 (0.70-2.21)

Referent
1.04 (0.59-1.82)

Referent
1.51 (0.97-2.36)

Referent
1.33 (0.59-3.00)

Referent
3.02 (1.55-5.90)†

Referent
2.45 (1.05-5.70)*

Referent
2.90 (1.53-5.49)†

Referent
2.90 (1.42-5.92)†

Referent
1.43 (0.54-3.81)
1.60 (1.29-1.98)‡

Referent
1.85 (0.62-5.46)
1.25 (1.08-1.44)†

Referent
1.00 (0.44-2.27)
1.34 (1.11-1.62)†

Referent
1.34 (0.47-3.80)
1.14 (0.86-1.49)

Referent
1.08 (0.26-4.46)
2.80 (1.08-7.27)*

Referent
1.98 (0.39-9.97)
2.03 (0.89-4.60)

Referent
0.89 (0.15-5.27)
3.27 (1.26-8.46)*

Referent
2.25 (0.42-12.14)
3.98 (1.42-11.21)*

%w=weighted percent, aOR=adjusted odds ratio, H+PPR=heroin and prescription pain reliever use, HS=high school, HO=heroin use only, IDU=injection drug use, N=sample size,
NSDUH=national survey on drug use and health, PPR=prescription pain relievers use, SUD=substance use disorder.
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001
a
Comprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race
b
Comprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”
c
K6 scale measures symptoms of psychological distress during the past 30 days, a score ≥ 13 indicates severe psychological distress within past year
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Supplemental Table 2.1: Reasons why individuals felt they didn’t need treatment or additional
treatment in the past year (N=382)
Barrier
Explanation
N (%W)
Overall†
Readiness
Because not ready to stop use
21 (4.6)
4.6
Barrier
Because of cost
11 (2.1)
Financial
6.2
Barrier
Because no insurance
17 (4.3)
Because no transportation
8 (2.0)
Because treatment wanted not offered
6 (1.7)
Structural
Because No openings in the program
6 (1.2)
4.9
Barrier
Because didn’t have time
6 (1.4)
Because didn’t know where to go
4 (0.8)
Because neighbors have negative opinion
13 (3.2)
Stigma
Because have negative effect on job
14 (2.6)
4.4
Barrier
Because didn’t want others to find out
7 (1.5)
These responses are given for the question: “Which of these statements explain why you did not get the treatment or
counseling you needed for your use of [substance]?”
†
Weighted percentages
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Supplemental Table 2.2: Bivariate associations between predisposing, enabling, and need
characteristics with perceived treatment barriers among insured adults with past year opioid misuse
(NSDUH 2015-2017) (N=6,029)
Readiness Barrier

Financial Barrier

Structural Barrier

Stigma-Related Barrier

Referent
1.13 (0.62-2.05)
0.83 (0.48-1.43)
0.33 (0.12-0.88)*

Referent
1.79 (0.86-3.74)
1.10 (0.57-2.13)
0.23 (0.02-2.24)

Referent
1.76 (1.05-2.95)†
0.84 (0.42-1.69)
0.48 (0.16-1.44)

Referent
0.88 (0.51-1.52)
0.67 (0.28-1.61)
0.39 (0.09-1.65)

0.74 (0.43-1.26)
Referent

0.84 (0.50-1.40)
Referent

0.69 (0.38-1.25)
Referent

0.67 (0.37-1.22)
Referent

Referent
0.45 (0.21-0.98)*
1.15 (0.53-2.52)
1.06 (0.59-1.91)

Referent
0.66 (0.20-2.17)
1.30 (0.32-5.24)
0.19 (0.06-0.59)*

Referent
0.87 (0.38-2.00)
2.04 (0.85-4.87)
1.12 (0.43-2.94)

Referent
0.36 (0.08-1.75)
1.61 (0.50-5.20)
0.56 (0.21-1.50)

Referent
2.67 (1.74-4.12)‡

Referent
1.63 (0.84-3.19)

Referent
2.35 (1.27-4.35)†

Referent
2.21 (1.07-4.57)*

Referent
1.19 (0.72-1.95)

Referent
0.67 (0.33-1.34)

Referent
0.69 (0.37-1.27)

Referent
1.22 (0.54-2.79)

1.81 (1.12-2.92)*
Referent

2.55 (1.30-5.03)†
Referent

2.01 (1.20-3.38)†
Referent

3.05 (1.71-5.45)†
Referent

Referent
1.03 (0.59-1.81)
1.11 (0.63-1.94)

Referent
1.31 (0.73-2.36)
1.68 (0.70-4.02)

Referent
1.17 (0.71-1.92)
1.62 (0.77-3.42)

Referent
2.27 (1.15-4.46)
2.04 (0.72-5.74)

Referent
2.47 (1.53-4.00)*
3.54 (1.73-7.25)*

Referent
2.73 (1.56-4.82)†
2.95 (1.06-8.17)†

Referent
3.79 (2.16-6.64)†
2.28 (0.85-6.10)

Referent
1.29 (0.74-2.22)
1.61 (0.54-4.79)

Referent
0.88 (0.47 – 1.68)
1.41 (0.77 – 2.57)

Referent
0.82 (0.40-1.68)
1.53 (0.61-2.19)

Referent
1.26 (0.64-2.46)
0.92 (0.50-1.69)

Referent
0.72 (0.27-1.98)
1.13 (0.58-2.21)

Referent
1.70 (1.05-2.74)*

Referent
1.49 (0.94-2.37)

Referent
2.17 (1.34-3.50)†

Referent
1.67 (0.84-3.36)

Referent
5.51 (3.13-9.73)‡

Referent
3.85 (1.73-8.60)†

Referent
4.73 (2.55-8.77)‡

Referent
4.31 (2.07-8.96)†

Referent
3.67 (1.88-7.18)†
1.90 (1.60-2.25)‡

Referent
4.41 (2.24-8.70)‡
1.52 (1.33-1.73)‡

Referent
18.12 (9.90-33.17)†
1.60 (1.38-1.86)‡

Referent
3.30 (1.66-6.56)†
1.42 (1.19-1.71)†

Referent
1.56 (0.46-5.32)
6.20 (3.20-12.01)†

Referent
3.74 (0.88-15.81)
5.34 (2.76-10.27)*

Referent
1.29 (0.21-7.90)
5.91 (3.11-11.22)†

Referent
3.14 (0.70-14.02)
5.60 (2.68-11.69)*

OR (95% CI)

Age
18-25 Years
26-34 Years
35-49 Years
50-64 Years
Sex
Male
Female
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Sexual Identity
Heterosexual
Lesbian, Gay, or Bisexual
Education Level
Less than HS or HS grad
Some college, AS, or CG
Total family income
< $20,000
> $20,000
Urbanicity
Large metro
Small metro
Non-metro
Insurance Type
Private Insurance
Medicaid
Othera
Year
2015
2016
2017
Self-Reported Health
Excellent/Very Good
Fair/Poor
Severe psychological distress
No < 13
Yes ≥ 13
Past Year IDU
No
Yes
Additional SUD
Past Year Opioid Misuse
PPR
HO
H+PPR

OR (95% CI)

OR (95% CI)

OR (95% CI)

HO=heroin use, PPR=pain reliever use, H+PPR= heroin and pain reliever use, SUD=substance use disorder, IDU=injection drug use,
HS=high school, N=sample size, %w=weighted percent, NSDUH=national survey on drug use and health, OR=odds ratio, 95% CI=95%
confidence interval
NOTE: Boldface indicates statistical significance; *α<.05, †α<.01, ‡α<.0001
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Figure 3.1: Schematic representation of the latent variable
Adapted from Uebersax, 1994

Figure 3.2: Schematic representation of the latent class model
Adapted from Uebersax, 1994
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Table 3.1: Latent class analysis model fit statistics for classes 2-6
Classes

BICss

Entropy

2-CLASS
3-CLASS
4-CLASS
5-CLASS
6-CLASS

55384.4
52734.0
52502.9
52121.0
52078.8

0.787
0.837
0.709
0.747
0.768

p-value for
LMRa
<.0001
<.0001
<.0001
0.0001
0.2054

Loglikelihood

Npar

-27600.8
-26228.6
-26066.0
-25827.9
-25759.8

33
50
67
84
101

p-value for
BLRTa
<.0001
<.0001
<.0001
<.0001
<.0001

BICss=Sample Size Adjusted Bayes Information Criteria, BLRT=Bootstrapped Likelihood Ratio Test, LCA=Latent Class Analysis, LMR=Lo-Mendell-Rubin
Adjusted Likelihood Ratio Test, Npar=Number of parameters
a
LMR and BLRT compare the increase in model fit between the k-1and k class models. Significant values indicate that the model has a statistically better fit than
the model that preceeded it.

Table 3.2: Conditional probabilities of past year substance use among individuals reporting past year opioid
misuse for three classes of polysubstance use (NSDUH 2015-2017) (N=6095)
Overalla
C1: Heroin
C2: PPR users C3: PPR users
(n=6095, 100%)
injectors with
with low PSU with high PSU
Licit/Near licit Substance Use
Binge alcohol
Marijuana
Prescription Drug Misuse
PPR
Tranquilizers
Stimulants
Sedatives
Illicit Substance Use
Heroin
Cocaine
Crack
Hallucinogens
Inhalants
Methamphetamines
Injection Drug Use
Used Needle to Inject Cocaine
Used Needle to Inject Heroin
Used Needle to Inject Methamphetamines
Used Needle to Inject Other Drug

(n=4000, 65.6%)

(n=1622, 26.6%)

n (%)
3235 (53.1)
3437 (56.4)

high PSU
(n=473, 7.8%)
n (%c)
188 (39.8)
337 (71.3)

n (%c)
1704 (42.6)
1500 (37.5)

n (%c)
1312 (80.9)
1551 (95.6)

5934 (97.5)
1627 (26.8)
1242 (20.4)
340 (5.6)

350 (74.1)
202 (42.7)
122 (25.8)
49 (10.3)

3976 (99.4)
548 (13.7)
276 (6.9)
136 (3.4)

1619 (99.8)
853 (52.6)
814 (50.2)
151 (9.3)

511 (8.4)
1097 (18.0)
221 (3.6)
976 (16.0)
243 (4.0)
385 (6.3)

423 (89.5)
257 (54.4)
158 (33.3)
113 (23.8)
38 (8.0)
175 (37.0)

32 (0.8)
44 (1.1)
0 (0)
48 (1.2)
44 (1.1)
44 (1.1)

63 (3.9)
756 (46.6)
57 (3.5)
775 (47.8)
152 (9.4)
157 (9.7)

98 (1.6)
277 (4.5)
142 (2.3)
159 (2.6)

90 (19.1)
271 (57.3)
131 (27.6)
140 (29.7)

0 (0)
0 (0)
0 (0)
8 (0.2)

3 (0.2)
0 (0)
8 (0.5)
6 (0.4)

%c=Conditional probability of class membership, N=Sample size, NSDUH=National survey on drug use and health, PPR=Prescription pain reliever,
PSU=Polysubstance use
a
Overall column provides the past-year substance and injection drug use for the entire population.
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Figure 3.3: Latent classes of past year polysubstance use
ETOH=alcohol, PPR=prescription pain relievers
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Table 3.3: Sociodemographic characteristics of insured opioid-misusing adults by latent class of
polysubstance use (NSDUH 2015-2017) (N=6,095)
TOTAL
(N=6,095)

Age‡
18-25 years
26-34 years
35-49 years
50-64 years
Sex‡
Male
Female
Race/ethnicity†
Non-Hispanic White
Non-Hispanic Black
Hispanic
Othera
Sexual identity‡
Heterosexual
Lesbian, gay or bisexual
Education level‡
HS graduate or less
Some college-graduate
Total family income‡
< $20,000
> $20,000-$49,000
Urbanicity
Large metro
Small metro
Non-metro
Insurance type‡
Private insurance
Medicaid
Otherb
Survey year
2015
2016
2017
Self-reported health‡
Fair/poor
Excellent/very good
Severe psychological distressc‡
No < 13
Yes ≥ 13
Past year tobacco use‡
No
Yes
Average cigarette use per day
for past 30 days‡
Never used/don’t smoke
<1 – 1 per day
2 to 5 per day
6 to 15 per day
16 to > 35 per day

N (%w)

C1: Heroin injectors
with high PSU
(N=473)
N (%w)

C2: PPR users with
low PSU
(N=4000)
N (%w)

C3: PPR users with high
PSU
(N=1622)
N (%w)

2783 (26.0)
1451 (24.1)
1386 (27.9)
475 (22.1)

178 (20.7)
150 (33.5)
105 (26.5)
40 (19.4)

1495 (19.0)
987 (22.6)
1119 (32.0)
399 (26.5)

1110 (51.7)
314 (26.0)
162 (14.4)
36 (7.9)

3067 (53.4)
3028 (46.6)

284 (65.9)
189 (34.1)

1830 (48.9)
2170 (51.1)

953 (64.2)
669 (35.8)

3979 (69.6)
664 (10.2)
572 (6.3)
880 (13.9)

354 (73.1)
29 (11.6)
39 (4.2)
51 (11.1)

2480 (68.0)
532 (11.2)
386 (6.6)
602 (14.2)

1145 (73.8)
103 (6.2)
147 (6.3)
227 (13.6)

5188 (89.4)
841 (10.6)

397 (89.2)
68 (10.8)

3470 (90.9)
484 (9.1)

1321 (84.6)
289 (15.4)

2544 (37.4)
3551 (62.6)

274 (51.9)
199 (48.1)

1620 (36.0)
2380 (64.0)

650 (36.9)
972 (63.1)

1590 (21.6)
4505 (78.4)

198 (44.2)
275 (55.8)

939 (18.4)
3061 (81.6)

453 (24.3)
1169 (75.7)

2707 (56.9)
2224 (30.7)
1164 (12.4)

199 (56.1)
174 (31.2)
100 (12.7)

1796 (57.5)
1439 (30.0)
765 (12.5)

712 (55.0)
611 (32.9)
299 (12.1)

3704 (64.0)
1882 (27.3)
509 (8.7)

147 (31.4)
283 (59.1)
43 (9.5)

2463 (65.9)
1211 (25.2)
326 (9.0)

1094 (69.7)
388 (22.9)
140 (7.4)

2190 (34.5)
1988 (34.3)
1917 (31.3)

132 (28.8)
180 (36.3)
161 (34.9)

1463 (34.8)
1283 (34.1)
1254 (31.1)

595 (35.3)
525 (34.0)
502 (30.7)

2971 (49.8)
3123 (50.2)

303 (63.7)
170 (36.3)

1976 (50.0)
2023 (50.0)

692 (44.3)
930 (55.7)

3877 (68.3)
2218 (31.7)

240 (52.1)
233 (47.9)

2725 (72.7)
1275 (27.3)

912 (59.3)
710 (40.7)

2037 (39.2)
4058 (60.8)

26 (8.2)
447 (91.8)

1789 (49.4)
2211 (50.6)

222 (15.6)
1400 (84.4)

2990 (53.8)
572 (7.7)
834 (12.3)
893 (12.5)
803 (13.6)

59 (16.6)
26 (6.1)
6 (15.2)
153 (25.7)
169 (36.4)

2411 (63.3)
278 (6.0)
437 (9.9)
442 (9.5)
430 (11.3)

520 (34.9)
268 (14.3)
331 (19.4)
298 (18.1)
204 (13.4)

%w=weighted percent, HS=high school, N=sample size, NSDUH=National survey on drug use and health, PPR=prescription pain relievers use, PSU=Polysubstance
use NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001
a
Comprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race
b
Comprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”
c
K6 scale measures symptoms of psychological distress during the past 30 days, a score ≥ 13 indicates severe psychological distress within the past year
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Table 3.4: Association between classes of polysubstance use and perceived barriers to accessing treatment
for substance use disorder (NSDUH 2015-2017) (N=6,029)

Classes of PSU

C1: Heroin injectors with
high PSU
C2: PPR users with low
PSU
C3: PPR users with high
PSU

Readiness Barrier

Financial Barrier

Structural Barrier

aORa (95% CI)

aORa (95% CI)

aORa (95% CI)

Stigma-Related
Barrier
aORa (95% CI)

3.11 (1.43-6.77)†

1.76 (0.64-4.85)

2.42 (1.22-4.79)*

3.13 (1.31-7.48)*

Referent

Referent

Referent

Referent

2.89 (1.41-5.93)†

1.58 (0.75-3.33)

1.65 (0.83-3.26)

2.28 (0.99-5.24)

95%CI=95% confidence interval, aOR=adjusted odds ratio, N=sample size, NSDUH=national survey on drug use and health, PPR=prescription pain reliever,
PSU=polysubstance use, SUD=substance use disorder.
a
Model adjusted for age, sex, race/ethnicity, sexual identity, education level, total family income, urbanicity, insurance type, year, self-reported health, severe
psychological distress, and average number of cigarettes/day.
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001
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Supplemental Table 3.1: Specific drugs making up substance use categories114
Classification Question for Misuse

Hallucinogens

“How long has it been since you have
used any hallucinogen?”

Inhalants

“Have you ever inhaled any of the
following substances, even once, for
kicks or to get high?”

Pain Relievers

“Have you ever, even once, used any
prescription pain reliever in a way that
a doctor did not direct the respondent
to use it”

Sedatives

“Have you ever, even once, used any
prescription sedatives in a way that a
doctor did not direct the respondent to
use it”

Stimulants

“Have you ever, even once, used any
prescription stimulants in a way that a
doctor did not direct the respondent to
use it”

Tranquilizers

“Have you ever, even once, used any
prescription tranquilizers in a way that
a doctor did not direct the respondent
to use it”

Drugs Included
LSD, also called 126 "acid"; PCP, also called "angel dust" or phencyclidine; peyote;
mescaline; psilocybin, found in mushrooms; "Ecstasy" or "Molly," also known as MDMA;
ketamine, also called "Special K" or "Super K"; DMT, also called imethyltryptamine, AMT, also called alphamethyltryptamine, or Foxy, also called 5-MeO-DIPT; Salvia divinorum; and any other hallucinogen besides
the ones that have been listed.
amyl nitrite, "poppers," locker room odorizers, or "rush"; correction fluid, degreaser, or cleaning fluid; gasoline
or lighter fluid; glue, shoe polish, or toluene; halothane, ether, or other anesthetics; lacquer thinner or other
paint solvents; lighter gases, such as butane or propane; nitrous oxide or "whippets"; felt-tip pens, felt-tip
markers, or magic markers; spray paints; computer keyboard cleaner, also known as air duster; some other
aerosol spray; and any other inhalant besides the ones that have been listed.
Hydrocodone products (Vicodin®, Lortab®, Norco®, Zohydro® ER, or generic hydrocodone);
Oxycodone products (OxyContin®, Percocet®, Percodan®, Roxicodone®, or generic oxycodone); Tramadol
products (Ultram®, Ultram® ER, Ultracet®, generic tramadol, or generic extended-release tramadol);
Codeine products (Tylenol® with codeine 3 or 4 or generic codeine pills); Morphine products (Avinza®,
Kadian®, MS Contin®, generic morphine, or generic extended-release morphine); Fentanyl products
Duragesic®, Fentora®, or generic fentanyl); Buprenorphine products (Suboxone®, generic buprenorphine,
or generic buprenorphine plus naloxone); Oxymorphone products (Opana®, Opana® ER, generic
oxymorphone, or generic extended-release oxymorphone), 148 Demerol®; Hydromorphone products
(Dilaudid® or generic hydromorphone, or Exalgo® or generic extended-release hydromorphone); Methadone;
Any other prescription pain reliever*
Zolpidem products (Ambien®, Ambien® CR, generic zolpidem, or generic extended-release zolpidem);
eszopiclone products (Lunesta® or generic eszopiclone); zaleplon products (Sonata® or generic zaleplon);
benzodiazepine sedatives (flurazepam [also known as Dalmane®], temazepam products [Restoril®, or
generic temazepam], or triazolam [Halcion® or generic triazolam]); barbiturates (Butisol®, Seconal®, or
phenobarbital); or any other
Prescription sedative.
Amphetamine products (Adderall®, Adderall® XR, Dexedrine®, Vyvanse®, generic dextroamphetamine,
generic amphetaminedextroamphetamine combinations, or generic extended-release amphetaminedextroamphetamine combinations); methylphenidate products (Ritalin®, Ritalin® LA, Concerta®,
Daytrana®, Metadate CD, Metadate ER, Focalin, Focalin XR, generic methylphenidate, generic extendedrelease methylphenidate, generic
dexmethylphenidate, or generic extended-release dexmethylphenidate); anorectic (weight-loss) stimulants
(Didrex®, benzphetamine, Tenuate®, diethylpropion, phendimetrazine, or phentermine); Provigil®; or any
other prescription stimulant.
benzodiazepine tranquilizers (including alprazolam products [Xanax®, Xanax® XR, generic alprazolam, or
generic extendedrelease alprazolam]; lorazepam products [Ativan® or generic
lorazepam]; clonazepam products [Klonopin® or generic clonazepam]; or diazepam products [Valium® or
generic diazepam]); muscle relaxants (cyclobenzaprine [also known as
Flexeril®] or Soma®); or any other prescription tranquilizer.
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Supplemental Table 3.2: Adjusted odds ratios for perceived barriers to accessing substance use disorder
treatment in the past year by insured adults reporting past year opioid misuse (NSDUH 2015-2017)
Age
18-25 years
26-34 years
35-49 years
50-64 years
Sex
Male
Female
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Othera
Sexual identity
Heterosexual
Lesbian, gay, or bisexual
Education level
HS graduate or less
Some college-graduate
Total family income
< $20,000
> $20,000
Urbanicity
Large metro
Small metro
Non-metro
Insurance type
Private insurance
Medicaid
Otherb
Survey year
2015
2016
2017
Self-reported health
Excellent/very good
Fair/poor
Severe psychological distressc
No < 13
Yes ≥ 13
Average cigarette use per day
for past 30 days
Non-Smoker
<1-1 per day
2-5 per day
6-15 per day
16->35 per day
Classes of PSU
C1: Heroin injectors with high
PSU
C2: PPR users with low PSU
C3: PPR users with high PSU

Readiness Barrier
aORa (95% CI)

Financial Barrier
aORa (95% CI)

Structural Barrier
aORa (95% CI)

Stigma-Related Barrier
aORa (95% CI)

Referent
1.41 (0.74-2.69)
1.49 (0.83-2.67)
0.62 (0.22-1.72)

Referent
1.69 (0.79-3.62)
1.22 (0.63-2.37)
0.28 (0.03-2.86)

Referent
1.76 (0.95-3.26)
1.16 (0.58-2.31)
0.76 (0.21-2.73)

Referent
1.16 (0.53-2.54)
1.08 (0.36-3.21)
0.76 (0.11-4.99)

0.89 (0.49-1.61)
Referent

0.87 (0.51-1.51)
Referent

0.75 (0.39-1.46)
Referent

0.74 (0.42-1.32)
Referent

Referent
0.44 (0.19-1.02)
1.02 (0.47-2.21)
1.00 (0.50-2.00)

Referent
0.96 (0.29-3.17)
1.36 (0.39-4.71)
0.24 (0.07-0.77)*

Referent
1.01 (0.38-2.67)
2.22 (0.95-5.17)
1.43 (0.50-4.08)

Referent
0.53 (0.09-3.16)
1.82 (0.59-5.57)
0.77 (0.27-2.22)

Referent
1.66 (0.99-2.80)

Referent
1.26 (0.62-2.54)

Referent
1.61 (0.84-3.06)

Referent
1.51 (0.71-3.21)

Referent
1.36 (0.81-2.29)

Referent
1.03 (0.49-2.16)

Referent
1.02 (0.59-1.77)

Referent
1.55 (0.66-3.61)

1.21 (0.70-2.11)
Referent

1.80 (0.81-3.98)
Referent

1.02 (0.53-1.97)
Referent

2.53 (1.27-5.03)†
Referent

Referent
0.81 (0.44-1.51)
0.94 (0.51-1.74)

Referent
0.97 (0.55-1.70)
1.00 (0.48-2.09)

Referent
0.97(0.58-1.61)
1.19 (0.60-2.36)

Referent
1.90 (0.93-3.88)
1.66 (0.61-4.50)

Referent
3.47 (1.67-7.23)†
1.88 (1.06-3.34)*

Referent
2.16 (0.80-5.84)
1.15 (0.49-2.71)

Referent
1.53 (0.61-3.83)
1.85 (0.98-3.49)

Referent
1.08 (0.38-3.10)
0.55 (0.23-1.34)

Referent
0.81 (0.42-1.55)
1.32 (0.72-2.42)

Referent
0.80 (0.41-1.59)
1.10 (0.56-2.17)

Referent
1.15 (0.60-2.21)
0.82 (0.44-1.52)

Referent
0.68 (0.25-1.82)
0.99 (0.52-1.86)

Referent
1.35 (0.74-2.45)

Referent
0.86 (0.48-1.53)

Referent
1.32 (0.85-2.07)

Referent
1.22 (0.52-2.88)

Referent
3.48 (1.92-6.29)‡

Referent
2.51 (1.15-5.48)*

Referent
2.90 (1.58-5.34)†

Referent
2.77 (1.44-5.34)†

Referent
1.51 (0.61-3.76)
2.45 (1.12-5.35)*
1.57 (0.70-3.53)
0.85 (0.35-2.02)

Referent
1.53 (0.31-7.55)
1.49 (0.34-6.48)
4.98 (2.21-11.23)‡
6.86 (3.07-15.36)†

Referent
2.77 (0.85-9.04)
5.52 (1.90-16.03)‡
4.93 (1.74-13.98)†
5.74 (2.50-13.16)†

Referent
0.73 (0.15-3.53)
3.59 (1.06-12.22)*
1.72 (0.53-5.51)
3.40 (1.27-9.15)*

3.11 (1.43-6.77)†

1.76 (0.64-4.85)

2.42 (1.22-4.79)*

3.13 (1.31-7.48)*

Referent
2.89 (1.41-5.93)†

Referent
1.58 (0.75-3.33)

Referent
1.65 (0.83-3.26)

Referent
2.28 (0.99-5.24)

%w=weighted percent, aOR=adjusted odds ratio, H+PPR=heroin and prescription pain reliever use, HS=high school, HO=heroin use only, IDU=injection drug use, N=sample size,
NSDUH=national survey on drug use and health, PPR=prescription pain relievers use, SUD=substance use disorder.
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001
a
Comprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race
b
Comprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”
c
K6 scale measures symptoms of psychological distress during the past 30 days, a score ≥ 13 indicates severe psychological distress within the past year

96

Table 4.1: Demographic and incident-related characteristics for nonfatal
opioid overdoses in Chesterfield County and the Control County 2016-2020e
(N=1,888)
Age‡
18-24 years
25-34 years
35-44 years
45-54 years
55-64 years
≥ 65 years
Sexd*
Female
Male
Race/ethnicityd‡
Non-Hispanic White
Non-Hispanic Black
Other
Overdose year‡
2016
2017
2018
2019
2020
Overdose locationd†
Private residence
Public area
Residential facility
Route of naloxone
administrationd‡
IV
IN
IM/ otherb
Combinedc
Total dose of naloxone
0.4 – 0.99 mg
1.0 – 1.9 mg
2.0 – 2.9 mg
3.0 – 4.9 mg
≥ 5.0 mg

Chesterfield
N=1,009 (6.0%)

Control
N=879 (5.3%)

Total
N=1,888

120 (11.9)
385 (38.2)
211 (20.9)
151 (15.0)
86 (8.5)
56 (5.6)

122 (13.9)
264 (30.0)
178 (20.3)
161 (18.3)
96 (10.9)
58 (6.6)

242 (12.8)
649 (34.4)
389 (20.6)
312 (16.5)
182 (9.6)
114 (6.0)

392 (38.9)
617 (61.2)

287 (33.1)
579 (66.9)

679 (36.2)
1196 (63.8)

740 (74.1)
225 (22.5)
34 (3.4)

554 (65.3)
272 (32.1)
22 (2.6)

1294 (70.0)
497 (29.9)
56 (3.0)

224 (22.2)
244 (24.2)
244 (24.2)
275 (27.3)
22 (2.2)

191 (21.7)
223 (25.4)
214 (24.4)
231 (26.3)
20 (2.3)

415 (22.0)
467 (24.7)
458 (24.2)
506 (26.8)
42 (2.2)

684 (67.9)
308 (30.6)
15 (1.5)

521 (59.5)
322 (36.8)
33 (3.8)

1205 (64.0)
630 (33.5)
48 (2.5)

285 (28.6)
602 (60.4)
16 (1.6)
94 (9.4)

483 (56.0)
243 (28.2)
24 (2.8)
113 (13.1)

768 (41.3)
845 (45.4)
40 (2.2)
207 (11.1)

86 (8.6)
134 (13.5)
236 (23.7)
437 (43.9)
103 (10.3)

118 (13.9)
264 (31.1)
335 (39.5)
122 (14.4)
9 (1.1)

204 (11.1)
398 (21.6)
571 (31.0)
559 (30.3)
112 (6.1)

%= percent, IM=intramuscular, IN=intranasal, IV=intravenous, mg=milligrams, N=sample size
*
α<.05, †α<.01, ‡α<.0001
a
All values reported as percentages within each column as N (%)
b
Other included all intra-muscular routes and any other routes of medication administration not already mentioned,
including ET tubes, etc.
c
Combined is any individual who was administered naloxone through multiple routes
d
Frequencies may not add up due to missing values
e
February 1st 2016 – January 31st 2020
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Table 4.2: Single interrupted time series of monthly nonfatal opioid overdoses in
Chesterfield Countya (2016-2020)
Intercept
Pre-Intervention Slope
Change in Level (pre-post interruption)
Change in Slope (pre-post interruption)
Post-Intervention Slope

P
β0
β1
β2
β3
β1 + β3

Estimate
2.877163
0.013664
-0.326317
0.001356
0.01502

SE
0.140802
0.009478
0.185637
0.013343
0.002959

p-value
<.0001
0.1565
0.0857
0.9195
---

SE=standard error, P=parameter
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 – January
31st 2020.
a
Estimates adjusted for overdispersion

Figure 4.1: Single interrupted time series analysis of nonfatal opioid overdoses in Chesterfield
County
Solid line= modeled trend for the monthly number of nonfatal opioid overdoses, dashed line = counterfactual, or predicted
trend if no intervention had been implemented.
Area shaded in gray represents the post-intervention period (February 1st 2018 – January 31st 2020).
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Table 4.3: Multiple interrupted time series for monthly nonfatal opioid overdoses
comparing Chesterfield County to Control Countya (2016-2020)
Intercept
Pre-Intervention slope (Control)
Δ Level (pre-post interruption) (Control)
Δ Slope (pre-post interruption) (Control)
Δ Pre-intervention level (Treatment vs. Control)
Δ Pre-intervention slope (Treatment vs. Control)
Δ Differences in level (pre-to-post intervention)
(Treatment vs. Control)
Δ Differences in slope (pre-to-post intervention)
(Treatment vs. Control)

Parameter
β0
β1
β2
β3
β4
β5
β6
β7

Estimate
2.851519
-0.003269
-0.148562
0.024081
0.025645
0.016933

SE
0.145439
0.010277
0.204838
0.014280
0.198878
0.013748

p-value
<.0001
0.7512
0.4702
0.0953
0.8977
0.2214

-0.177755

0.271924

0.5150

-0.022725

0.019214

0.2401

SE=standard error
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 – January 31st 2020.
a
Estimates adjusted for overdispersion

Figure 4.2: Multiple iteration time series analysis for Chesterfield County and the Control
County
Solid red line= modeled trend for the number of monthly nonfatal opioid overdoses for Chesterfield County, Solid blue line
= modeled trend for the number of monthly nonfatal opioid overdoses in the control county
Area shaded in gray represents the post-intervention period (February 1st 2018 – January 31st 2020).
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Supplemental Table 4.1: Demographic and population characteristics for Chesterfield
County and the Control County (2018)
Chesterfield Countya Control Countya
Total population
348,556
329,261
Age (years)
19-24 years
91365 (26.2%)
76767 (23.3%)
25-34 years
122578 (35.2%)
140009 (42.5%)
35-44 years
137517 (39.5%)
131226 (39.9%)
45-54 years
146533 (42.0%)
134387 (40.8%)
55-64 years
137025 (39.3%)
127513 (38.7%)
≥ 65 years
148957 (42.7%)
147537 (44.8%)
Sex
Male
168,039 (48.2%)
156,230 (47.4%)
Female
180,517 (51.8%)
173,031 (52.6%)
Race
White
243,545 (69.9%)
192,633 (58.5%)
Black or African American
88,221 (25.3%)
104,312 (31.7%)
American Indian and Alaska
2,337 (1.0%)
1,356 (0.4%)
Native
Asian or Pacific Islander
14,453 (4.1%)
30,960 (9.4%)
a

2018 Bridged-Race Population Estimates 1990-2018 Results, CDC WONDER

Supplemental Figure 4.1: Residual plot to assess for autocorrelation in the single
interrupted time series analysis of Chesterfield County
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Supplemental Figure 4.2: Estimates of autocorrelation for the single
interrupted time series model of Chesterfield County

ACF=autocorrelation function, resCF=residuals for Chesterfield
Horizontal blue lines represent 95% confidence intervals

Supplemental Table 4.2: Single interrupted time series of the monthly
number of nonfatal opioid overdoses in Chesterfield County (not adjusted
for overdispersion)
Intercept
Pre-Intervention Slope
Change in Level (pre-post interruption)
Change in Slope (pre-post interruption)
Post-Intervention Slope

P
β0
β1
β2
β3
β1 + β3

Estimate
2.877163
0.013664
-0.326317
0.001356
0.01502

SE
0.095470
0.006427
0.125870
0.009047
0.0102873

SE=standard error, P=parameter
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 –
January 31st 2020.

p-value
<.0001
0.03350
0.00953
0.88084
0.15093

Supplemental Table 4.3: Multiple interrupted time series for the number of monthly
nonfatal opioid overdoses comparing Chesterfield County to Control County (not
adjusted for overdispersion)
Intercept
Pre-Intervention slope (Control)
Δ Level (pre-post interruption) (Control)
Δ Slope (pre-post interruption) (Control)
Δ Pre-intervention level (Treatment vs. Control)
Δ Pre-intervention slope (Treatment vs. Control)
Δ Differences in level (pre-to-post intervention)
(Treatment vs. Control)
Δ Differences in slope (pre-to-post intervention)
(Treatment vs. Control)

P
β0
β1
β2
β3
β4
β5
β6
β7

Estimate
2.851519
-0.003269
-0.148562
0.024081
0.025645
0.016933

SE
0.102361
0.007233
0.144167
0.010050
0.139972
0.009676

p-value
<.0001
0.6513
0.3028
0.0166
0.8546
0.0801

-0.177755

0.191383

0.3530

-0.022725

0.013523

0.0929

SE=standard error, P=parameter
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 – January 31st 2020.
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Supplemental Figure 4.3: Residual plot to assess for
autocorrelation in the multiple interrupted times series analysis
of Control County and Chesterfield County

Supplemental Figure 4.4: Estimates of autocorrelation for the
multiple interrupted time series model for Chesterfield County
and Control County
ACF=autocorrelation function, MITSAres=residuals for multiple interrupted time series
Horizontal blue lines represent 95% confidence intervals
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